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Abstract 
Purpose: To investigate the incorporation of antibodies into the hydrophilic core of liposomes. 
This includes studying the development of antibody incorporation techniques, the impact 
antibody incorporation has on the size and shape of liposomes, and the ability for antibody 
loaded liposomes (AB-NLs) to penetrate SH-SY5Y neuroblastoma cells, giving insight into 
whether these types of liposomes can be used to delivery antibodies into cells. 
Methods: Antibodies were incorporated in the hydrophilic core during liposome preparation. 
Regular liposomes were then produced using a mini extruder, and then further processed for 
additional modifications. Analysis of liposome size and polydispersity index (PDI) was obtained 
by Dynamic Light Scattering (DLS), and then Transmission Electron Microscopy (TEM) was used 
to analyse the ultrastructure, size and lamellarity of formed vesicles. The Wako Assay 
measured the quantification of sphingomyelin in liposomes, which could then be used to 
produce liposomes with known lipid content. The ability for AB-NLs to penetrate SH-SY5Y cells 
was observed by a cell penetration assay. 
Results: AB-NLs had a tendency to clump, but were otherwise stable. Antibody incorporation 
was successful, yet efficiency was poor. AB-NLs were delivered into SH-SY5Y cells, enhanced 
by TAT attachment and Antibody fluorescence was observed. 
Conclusion: Development of current antibody incorporation techniques is essential for 
improved uptake. There is potential for AB-NLs as a therapeutic treatment with additional 
research. 
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CHAPTER ONE – Introduction 
 
1.1 Ageing and brain diseases 
Considerable neuronal death was once widely accepted to be an inevitable consequence of 
normal brain ageing, due to studies undertaken in the 1950s. However, it became clear that 
normal brain ageing is not associated with or explained by a  large-scale decrease in neuronal 
or synaptic number (Reviewed by Morrison and Hof, 1997) and that synaptic loss and neuron 
death is instead a consequence of neuropathogenic changes associated with 
neurodegenerative disorders. This process is selective, where certain circuits are disrupted 
that reflect the symptoms and pathogenesis of specific disorders. Since these observations are 
in the most part not a consequence of normal ageing, they can be used for understanding, 
diagnosis and treatment of age-related disorders. 
 
One way in which neuronal circuits can be disrupted is by the misfolding of proteins, which 
otherwise ensure normal cellular function. Protein disruption, as a result of altered 3D 
structure, can result in the formation of dysfunctional and misfolded proteins, capable of 
aggregation.  There are a group of brain diseases that are associated with the accumulation of 
these proteins (Table 1.1) that involve neuronal degeneration in specific brain areas (Soto, 
2003). These brain diseases are currently incurable, and are caused by an accumulation of 
multiple genetic and environmental factors (Martin, 1999). Alzheimer's Disease (AD) is the 










Synaptic dysfunction and perikaryal degeneration in the limbic system and associated 
areas, resulting primarily from the formation and accumulation of amyloid plaques 
and neurofibrillary tangles (Selkoe, 2001). 
Parkinson’s 
Disease (PD) 
Dopaminergic neuron cell loss in the substantia nigra (SN) and development of 
protein rich, intracytoplasmic Lewy bodies (LBs) (Shulman et al., 2011). 
Huntington’s 
Disease (HD) 
Neuronal loss in the striatum and cortex, as well as impact on nuclei in the thalamus, 
hypothalamus, subthalamic nucleus, SN and cerebellum. There is also reduction in 
tissue volume in the striatum and cortical white matter (Raymond et al., 2011). 
Dementia with 
Lewy bodies (DLB) 
Fluctuating cognitive impairment and visual hallucinations caused by sharing 
symptoms of both Alzheimer’s and Parkinson’s Disease (McKeith, 2004). 
Motor neuron 
disease (MND) 
Selective cell death of lower motor neurons in the spinal cord and brain stem and 
upper motor neurons in the motor cortex. Pathogenic mechanisms are multifactorial, 
one of which involves the presence of proteinaceous inclusions in the cells and 
neurofilament accumulation in the axons (Shaw, 2005). 
Frontotemporal 
dementia (FTD) 
Degeneration of the frontal and temporal cerebral lobes, linked to abnormal 
accumulation of disease specific proteins (Mackenzie and Neumann, 2016). 
Creutzfeldt-Jacob 
diseases (CJD) 
Spongiform appearance and neuronal cell loss in the central nervous system (CNS), 
proliferation of astrocytes and accumulation of an abnormally folded form of the host 
prion protein (PrP). There is also occasional deposition of amyloid plaques (Trevitt 
and Singh, 2003), often the cerebellum. 
 
Table 1.1: Age related brain diseases. Table shows the pathology of brain diseases associated with 








1.2 Alzheimer’s Disease - background 
In 1901, Alois Alzheimer documented a detailed report of symptoms from a 51-year-old 
woman (Auguste D.) at Frankfurt Hospital, who was observed to have severe cognitive 
dysfunction, memory impairment, altered behaviour, disorientation, delusions and 
progressive decline in language function (Reviewed by Moller and Graeber, 1998). While 
originally this case was seemingly indistinguishable from common senile dementia, the 
pathological-anatomical examination showed atrophy of the brain and changes in internal 
cortical cell clusters. Alzheimer described some pathological changes: senile plaques and 
neurofibrillary tangles (NFTs), which are now known respectively to contain fibrils composed 
of amyloid b-protein (Ab) and NFTs consisting of hyper-phosphorylated Tau protein (Hass and 
Selkoe, 2007) (Figure 1.1). As a result of Alzheimer’s observations, Emil Kraepelin coined the 
term “Alzheimer’s disease” (AD) for the illness in 1910 (Hoff and Hippus, 1989). Yet, it wasn’t 
until the late 1960s when AD became accepted as the most common basis for senile dementia. 
 
Figure 1.1: Comparison between normal and AD brain/neurons. The left shows healthy brain and 
neuronal cells, with absence of amyloid plaques and neurofibrillary tangles. The right shows an 
Alzheimer’s brain and neuronal cells, with senile amyloid plaques (red) and intracellular 
neurofibrillary tangles. The AD brain shows loss of cerebrocortical grey matter and enlarged fluid-
filled ventricles (Bird, 2008). 
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For many decades since the first case of AD was described by Alzheimer, many have tried to 
understand the underlying cause of this neurodegenerative disorder and determine how to 
cure it. In the 1970s, the first clue as to what might underlie AD came from the observation 
that neurons synthesizing and releasing acetylcholine usually underwent severe degeneration 
(Selkoe, 2001). As a result, three acetylcholinesterase inhibitors (donepezil, rivastigmine and 
galantamine) were developed and later approved to treat AD by enhancing acetylcholine 
levels in the synaptic cleft. However, these drugs do not target any causative underlying 
disease mechanisms, and do not slow the long-term progression of the disorder (Bullock and 
Dengiz, 2005). Instead, they provide only temporarily improved cognition by counterbalancing 
neurotransmitter disturbances, in addition to having many limitations and side effects 
(Yiannopoulou and Papageorgiou, 2013). 
 
In recent years, a consensus has developed and a rough outline of the disease progression and 
pathogenesis has emerged. Certainly, the likelihood of developing this neurodegenerative 
disorder increases with age (affecting both genders mainly over the age of 65) (Blennow et al., 
2006). This is noteworthy as advancements in modern medicine and technology have meant 
that average life expectancy has increased, leading to an increased AD burden worldwide. 
Today, AD affects approximately  36 million people worldwide, and this number is set to rise 









1.3 Clinical and neuropathological features of AD 
AD is characterized by the slow progressive impairment of episodic memory, and memory 
associated complications such as aphasia (difficulty speaking and understanding speech), 
agnosia (difficulty with object recognition) and apraxia (inability to make voluntary 
movements). This is combined with general symptoms of cognitive impairment such as 
impaired judgement, decision-making, mental uneasiness, disorientation and delusions 
(Blennow et al., 2006). These clinical features are  a result of underlying AD neuropathological 
changes. The most widely established, as in the original case described by Alois Alzheimer,  are 
the accumulation Ab plaques and NFTs. Other pathological changes include enlargement of 
brain ventricles, shrinkage of the hippocampus and cerebral cortex, general decrease in brain 
volume, gliosis, loss of grey matter and synaptic connections (including changes in 
acetylcholine transmission as a result of loss of cholinergic neurons), inflammation and 
extensive oxidative damage. Many of these pathological changes begin decades before clinical 
features can be observed (the preclinical phase) (Davies et al., 1988). 
 
During this preclinical phase, plaques and tangles accumulate until a threshold is met (that is 
different for each individual) when the first clinical symptoms start to appear. At this stage the 
term mild cognitive impairment (MCI) is given, which is based on close personal individuals 
verifying memory loss in a patient, supported by additional memory tests (Petersen, 2004). 
MCI is a heterogeneous entity as patients with MCI may go on to develop AD, or they may 
have a benign form of MCI or a different form of dementia (Gauthier et al., 2006). The 
conversion rate from MCI to AD with clinical dementia is 10-15% per year (Visser et al., 2005). 
 
In the past there has been difficulty in separating AD from other types of dementia. The term 
Alzheimer’s was originally used only for people with presenile onset of symptoms (before 65 
years of age), whereas senile dementia was used when the onset was after 65. However, 
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further research showed that amyloid plaques and neurofibrillary tangles are present both in 
AD and in senile dementia, which made clinical diagnosis uncertain. It is now clear that the 
plaque and tangle burden is more severe in the early onset form of AD than senile dementia, 
which has made them clinically distinguishable (Roth, 1986; Blennow et al., 1991). 
 
1.4 The genetics of Alzheimer’s Disease 
It is noteworthy that the estimated proportion of genetically based AD cases is uncertain. 
Many consider the genetic influence is responsible for between 10% and 50% of cases, whilst 
many other investigators believe that over time, all cases have a genetic cause (Selkoe, 2011). 
There are 4 widely confirmed genes in which mutations or polymorphisms are known to result 
in familial AD: amyloid precursor protein (APP) gene, the apolipoprotein E (ApoE) gene, 
presenilin 1 (PSEN1) and presenilin 2 (PSEN2), as well as many others in the process of 
confirmation (e.g. complement receptor). Missense mutations in the APP gene result in a 
general increase in Aβ (specifically Aβ42) as a consequence of an increase in amyloidogenic 
cleavages of APP by β- or g-secretases. Yet, since the missense mutations in the gene account 
to less than 0.01% of all Alzheimer’s cases, research of APP variations are primarily useful for 
understand pathogenic mechanisms of AD in general. APP can also cause AD via an increased 
dosage of the gene, which occurs in Down’s syndrome (trisomy 21) or in patients with APP 
microduplications on chromosome 21q and leads to overproduction of Aβ40 and Aβ42 (Rumble 
et al., 1989; Tokuda et al., 1997). In these cases, the lifelong increase in APP expression leads 
to the appearance of Aβ plaques as early as 12 years old (Selkoe, 2001). 
 
In the 1990’s , two groups of scientists identified an association between Apolipoprotein E4 
(APOE4) and AD that was later found to cause a 3-fold and 15-fold AD risk for heterozygotes 
and homozygotes respectively. ApoE is a glycoprotein, that is involved with the transport of 
cholesterol into cells (Pfrieger, 2003). The ApoE gene has three alleles (e2, e3, e4) that result 
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in 3 ApoE isoforms (E2, E3, E4) that differ by amino acid substitutions at residue 112 or 158 
(Mahley et al., 2006).  Inheritance of one or two of the e4 alleles was found to be an 
importance risk factor for AD and are now known to account for more than 30% of AD cases, 
and are the most influential genetic factor predisposing the disease (Corder et al., 1993; 
Saunders et al., 1993). Yet, some individuals homozygous for the ApoE4 show no symptoms 
throughout their lifetime. 
 
Dominantly inherited mutations in the genes encoding presenilin 1 (PS1) and presenilin 2 (PS2) 
lead to an aggressive form of AD with early onset (40 to 65 years old) (Rogaev et al, 1995; 
Levy-Lahad et al., 1995). Accumulation of hyper phosphorylated neurofibrillary Tau tangles 
are prominent features in AD neuropathology. However, mutations in the Tau gene have not 
been found to be associated with familial AD and they instead influence a form of 
frontotemporal dementia linked to chromosome 17 (FTDP-17), historically termed Pick’s 
disease (Hutton et al., 1998). Amyloid deposits are not a pathological feature of this form of 
frontotemporal dementia, and it is instead characterised by widespread tangle formation as a 
result of altered microtubule-binding properties of mutant tau (Lee et al., 2001). Transgenic 
mice and cell culture models have been used to analyse the effects that each of the four 
implicated genes in familial AD (Table 1.2). In all of these cases, the genetic variants were 
linked with an increase in the production or deposition of Aβ, providing strong evidence that 
AD is caused by accumulation of extracellular cerebral Aβ deposits. 
 
Advances in whole-genome analysis technology have revealed a rare genetic variant linked to 
AD. Triggering receptor expressed on myeloid cells 2 (TREM2) is a gene that encodes a 
receptor on myeloid cells that is essential for inflammatory responses. It is thought to increase 
AD risk 3-fold, a similar risk to one copy of the APOE e4 allele. 46 TREM2 genetic variants have 
been associated with AD. One genetic variant known as p.Arg47His (rs75932628) increases the 
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risk of AD by 2 to 3 times in some European and North American populations. However, more 
studies are required to strongly link other variants and to understand the neuropathology of 
such rare conditions (Yaghmoor et al., 2014; Carmona et al., 2018). 
 
 
Chromosome Gene Defect Inheritance Phenotype 




Increased production of all Aβ 
peptides (including Aβ42) 
19 ApoE4 
polymorphism 
Risk factor for late-
onset AD 
Increased density of Aβ40 
plaques 
14 PS1 mutations Autosomal 
dominant 
Increased production of Aβ42 
peptides 
1 PS2 mutations Autosomal 
dominant 
Increased production of Aβ42 
peptides 
6 TREM2 mutations Autosomal 
dominant 
Reduced microglial clustering 
around plaques  
 
Table 1.2: Genetic influence on familial AD. The loci and genes involved in increasing Aβ levels 
linked to AD. 
 
 
1.5 Disease frequency 
1.5.1 Incidence 
This late-onset neurodegenerative disease typically affects individuals over 65 years of age. 
There is a 1% annual risk of developing the disease between the age of 65-70, which rises to 
~8% for people over the age of 85. AD affects both genders, with a slightly higher incidence in 
women, and also African Americans. The median survival time for people with AD is ~4 years, 






Prevalence, or the proportion of individuals surviving with AD dramatically varies with age. 
The disease is rare under age 65, yet by age 85 over ~10% of the population have AD, with 
individuals ranging from mild to severe forms. The population of the UK over age 65 in 2016 
was 11.8 million, which means that the prevalence is almost 1.2 million people. This figure is 
set to increase as world populations age. Prevalence is higher and more sustained for African 
Americans, yet not amongst their respective native countries. These differences are likely to 
be due to a difference in lifestyle. For example: African Americans are more susceptible to 
vascular disease, which is linked with AD risk. Nevertheless, the lifetime risk remains 2 fold 
higher (Prince et al., 2016). 
 
1.6 Risk factors 
Epidemiology is a form of analytical research that in AD, typically involves the identification 
and analysis of risk factors in order to reduce disease burden. Advances that have occurred in 
genetic understanding have proven useful for the analysis of other risk factors. For example, 
identification of novel genetic susceptibilities give insight into particular behavioural and 
environmental risk factors involved. 
 
1.6.1 Ageing 
It has been historically difficult to differentiate between normal age-related brain changes and 
pathological changes such as those observed in AD. Brain cognition and function should 
remain separate when trying to understand these differences. It is obvious, however, that 





1.6.2 Education, early life and brain activity 
AD prevalence is significantly higher in individuals with poor education compared to those 
who have been well-educated (Stern et al., 1994). This sparked the theory that we have two 
independent ‘reserves’ (cognitive and brain) (Stern, 2012). This concept suggests that where 
brain reserve may be identical for two individuals (e.g. they have the same intensity of 
pathological changes or brain damage), differences in cognitive reserve may allow one person 
to cope more effectively than the other. It is considered that years of formal education acquire 
a cognitive reserve which protects individuals from AD later in life. 
 
1.6.3 Alcohol 
Excessive alcohol consumption has been known to cause dementia through acute toxicity and 
associated nutritional deficiencies. A French study found that individuals that drank red wine 
in moderate amounts were less likely to develop AD than heavy drinkers or abstainers, and 
another study reported that any alcohol in moderation is associated with reduced AD risk, due 
to antioxidant properties and its effect on lipid metabolism (Orgogozo et al., 1997; Ruitenberg 
et al., 2002). 
 
1.6.4 Smoking 
Studies have shown that smokers have a two- to fourfold increase in AD risk, particularly in 
those without an APO-e4 allele. Smoking is thought to increase dementia risk through an 
interaction with cerebral vessels. Although nicotine is thought to have beneficial effects, 
administration through smoking is still likely to be disadvantageous (Merchant et al., 1999; 





1.6.5 Down Syndrome 
Adults with Down’s syndrome develop the neuropathological changes associated with AD by 
the age of 40, but only some become demented. AD risk is increased two- to threefold within 
a family with a history of Down’s syndrome and individuals who have a child with Down’s 
syndrome are at higher risk of developing AD than those that have children with other types 
of mental retardation. It is thought that this might be due to a form of accelerated ageing that 
develops in these mothers that predisposes them to AD (Schupf et al., 2001). 
 
1.7 Amyloidosis and Alzheimer’s Disease 
Amyloid disease (amyloidosis) refers to a disease caused in parts of the body and some brain 
regions, as a result of amyloid fibril deposition. The deposited fibrils are 6-8 nm wide, and are 
composed of a key 39-43 amino acid peptide, termed Ab (amyloid b-peptide) (Glenner and 
Wong, 1984). Formed fibrils are resistant to proteolytic degradation, which leads to cell 
damage, organ dysfunction and ultimately death. All types of amyloid proteins share common 
properties: insolubility, fibrillar appearance with electron microscopy (Figure 1.2), b-pleated 
sheet conformation, and green birefringence under polarised light after Congo red staining. 
Although 26 proteins and 80 genetic variants have been linked with amyloid deposition, the 














   
Figure 1.2: Ab in amyloid and senile plaque formation. A) Fibrillar appearance of Ab fibrils, 
detected by electron microscopy with rotary metal shadowing. B) Ab peptide can be detected in 
the centre of senile plaques by immunostaining (Taken from: Allsop and Mayes, 2014). 
 
AD is the most common form of amyloidosis in humans. Amyloid deposits in AD are found at 
the centre of extracellular senile plaques, surrounded by abnormal nerve processes and 
microglia, located in the brain parenchyma of AD patients. Ab is the major component of AD 
parenchymal plaques, and can be detected in vivo using antibodies against Ab (Figure 1.2). 
This peptide is also the main constituent of cerebral amyloid deposits in Down’s syndrome, 
familial AD, sporadic cases of cerebral amyloid angiopathy and in normal ageing. 
 
1.8 Ab precursor protein (APP) 
The 39-42 amino acid Ab peptide is a product of a larger type I transmembrane precursor 
glycoprotein, known as amyloid-b precursor protein (APP). It is coded by a single multiexonic 
gene located on chromosome 21. This gene is more than 190 kb in length, and generates more 
than 10 isoforms of APP mRNA by alternative splicing. Only 4 isoforms of mRNA encode 
proteins that contain the Ab peptide (APP695, APP714, APP751 and APP770). The largest 
A B 
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isoform, APP770, is distinguished by its KPI (kunitz-type protease inhibitor) domain and an OX-
2 antigen domain. There is evidence to suggest that Ab is preferentially formed from APP695, 
the predominant isoform in the human brain, which lacks both domains described in APP770. 
12-14 amino acids of the Ab domain of APP reside in the transmembrane domain and the 
remaining residues lie outside (Barnham et al., 2003). APP is cleaved by proteolysis at three 
major sites. The a-secretase site (between residues 16-17 of the Ab region) prevents the 
formation of Ab, whereas the sequential cleavage at b- and g-secretase sites produces the full 





Figure 1.3: APP proteolytic processing pathway. A) Involves cleavage of APP by a-secretase at 
peptide bond 16-17, which prevents formation of the Ab fragment. B) involves cleavage of APP by 
b-secretase followed by g-secretase, to form the full Ab fragment, potentially leading to 
oligomerisation. Abbreviations: Amyloid precursor protein intracellular domain (AICD), Amyloid 
beta (Ab), soluble amyloid precursor protein a (sAPPa), soluble amyloid precursor protein b 





The ADAM (a disinterin and metalloproteinase) family have been identified as a-secretase, 
capable of cleaving APP at the a-site, with ADAM10 being the strongest candidate relevant to 
AD pathogenesis. The major b-secretase has been identified as BACE1 (b-site APP-cleaving 
enzyme 1) and the g-secretase is an intramembrane complex composed of nicastrin, PEN-2, 
APH-1 and presenilin. This enzyme has aspects of heterogeneity, which is responsible for the 
varied length of Ab between individuals, such as the two major isoforms (Ab42 and Ab40), 
both of which spontaneously aggregate in vitro into fibrils, but Ab42 does this more rapidly. 
After formation, Ab can be degraded by proteolysis or cleared into the peripheral blood 
stream via the blood brain barrier (BBB). Many enzymes are capable of degrading Ab: IDE 
(insulin-degrading enzyme), ECE (endothelin-converting enzyme), ACE (angiotensin-
converting enzyme) and Neprilysin, and the clearance across the BBB is mediated by LRP (low-
density lipoprotein receptor-related protein). RAGE (receptor for advanced glycation end 
products) controls it’s influx back to the brain (Hardy and Selkoe, 2002). Sporadic AD is due to 
an imbalance in these proteolytic events, or imbalance of Ab between the brain and the 
periphery. Whereas for Inherited cases, mutations in APP, PS1 and PS2 genes result in the 
overproduction of Ab (Allsop and Mayes, 2014). 
 
1.9 The amyloid cascade hypothesis 
Disruption of control mechanisms related to Ab production and clearance is thought to be 
linked directly to the pathogenesis of AD. This is known as the “amyloid cascade” hypothesis, 
whereby an imbalance in Ab production and clearance results in accumulation and 
aggregation of Ab through a cascade of events, leading to tangle formation and eventual 
neuronal cell death (Verdile et al., 2004), and is the most widely accepted mechanism for the 
formation of amyloid fibrils, which are thought to be toxic to nerve cells (Figure 1.4). Soluble 
oligomers, ADDLs (amyloid b-derived diffusible ligands) and protofibrils are thought to be the 
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predominant toxic forms of Ab (Walsh and Selkoe, 2007). They have also been shown to block 
long-term potentiation (LTP) and synaptic capacity, resulting in the loss of neuronal firing and 
deficits in memory processing (Tabner et al., 2005). Subsequently, oligomers (dimers and 
trimers) are considered a key drug target for the treatment of AD. Ab is also likely to act as a 
trigger to set off other damaging processes such as neurofibrillary tau formation, reactive 
oxygen species (ROS) formation and synaptic damage, all of which contribute to 









Figure 1.4: Aggregation of Ab into oligomers and amyloid fibrils. Oligomers are either ‘on 
pathway’ or ‘off pathway’ towards amyloid fibril formation. On pathway involves early 
intermediates leading to fibre formation. Off pathway involves monomer assembly directly into the 
nucleus required to initiate fibril formation. (Adapted from Allsop and Mayes, 2014). 
 
1.10 Neurofibrillary tangles (Tau) 
In AD, Tau pathology exists as abnormally folded Tau protein that forms hyperphosphorylated 
and aggregated bundles of paired helical filaments (PHF). In the AD brain these are seen as 
intraneuronal neurofibrillary tangles and are thought to be a downstream impact of Ab 
accumulation and aggregation (Braak et al., 1986). In humans, Tau proteins are encoded by a 
single microtubule-associated protein Tau (MAPT) gene mapped to chromosome 17q21 
(Himmler et al., 1989). Microtubules are tubular polymers that form part of the cytoskeleton. 
They provide structure and shape to the cytoplasm of eukaryotes and some bacteria and are 




involved in multiple cellular processes including intracellular transport of secretory vesicles 
and organelles as well as being major constituents of mitotic spindles in cell division. Healthy 
neurons contain microtubules, which contribute towards these cellular processes (Grundke-
Iqbal et al., 1986). Yet, abnormal folding leads to AD. In humans, alternative splicing of Tau 
pre-mRNA produces six isoforms of the protein that differ in containing three or four 
microtubule binding repeats (Goedert et al., 1989).  Tau interacts with tubulin and promotes 
its assembly into microtubules and stabilises their structure. In a normal mature healthy 
neuron, the amount of tubulin is tenfold greater than Tau (~2 µM) and nearly all Tau is 
continuously bound to microtubules in cells. Overexpression of Tau can cause microtubule 
bundling in vitro, but this has not been seen in AD or other tauopathies (Butner and Kirschner, 
1991). 
 
Degeneration of abnormally hyperphosphorylated Tau does occur in AD, which has been 
observed in all six Tau isoforms. Additional pathologies include conformational changes and 
truncation of Tau following hyperphosphorylation (Jicha et al., 1997; Novak et al., 1991). Total 
Tau is four to eight fold higher in AD brains than normal aged brains which is solely caused by 
the hyperphosphorylated version of Tau protein (Khatoon et al., 1992). This toxic form of Tau 
self-assembles into PHFs, forming neurofibrillary tangles. It also sequesters normal Tau as well 
as two other major neuronal microtubule associated proteins (MAP1 and MAP2), and this is 
likely to be the cause and/or contributor to the neurodegeneration observed in AD (Alonso et 
al., 1997; Alonso et al., 1996). It is evident however that 40% of this toxic Tau is not 
polymerised into neurofibrillary tangles and instead resides in the cytosol and this cytosolic 
tau does not bind tubulin or promote microtubule assembly, and instead inhibits assembly 
(Kopke et al., 1993). It remains clear that inhibiting abnormal hyperphosphorylated of Tau is a 




1.11 Current treatment of AD 
1.11.1 Ab drug therapy 
Cholinergic neurons that protrude from regions deep inside the brain, that are involved in 
memory, are selectively lost early in the course of AD. This led to the development of three 
acetylcholinesterase inhibitors, Galantamine, Donepezil and Rivastigmine, that have the 
ability to block the breakdown of acetylcholine at the synapse, in order to boost cholinergic 
transmission (Blennow et al., 2006). However, these drugs currently available for the 
treatment of AD only address symptoms of the disease and do not target any of the underlying 
disease mechanisms, or slow down the long term progression of the disorder. They also have 
many other side effects such as nausea, vomiting and liver toxicity in some cases 
(Yiannopoulou and Papageorgiou, 2013). An N-methyl-D-aspartate (NMDA) antagonist, 
memantine, is another drug used for the treatment of AD. The formation of learning and 
memory involves the NMDA receptor and its interaction with glutamate, and memantine is 
the only approved drug for advanced AD, yet still only has a temporary therapeutic impact 
(Areosa et al., 2004). 
 
Intermediates in the proteolysis of APP has been considered for AD therapy, targeting b- and  
g- secretases responsible for the production of Ab. BACE1, an integral membrane aspartyl 
protease required for b secretase activity, has been a target for inhibition without much 
success. g- secretase is involved in notch processing as well as APP proteolysis and so inhibition 
would lead to notch dysregulation, which is involved in essential development processes and 
dysfunction linked with cancer. a-secretase prevents the formation of Ab and has been 
considered as a therapeutic target, yet it is easier to produce therapies that inhibit rather than 





An active immunotherapeutic agent was developed in the form of an AD vaccine, termed 
AN1792, which involves triggering an immune response to aggregated Ab42. However, clinical 
trials were halted in phase three as patients developed encephalitis and brain inflammation 
Gilman et al., 2005). Following on from AN1792 therapy, anti Ab antibodies are in 
development, which can which can clear amyloid plaques from the brain. Passive 
immunotherapies have also been developed such as solanezumab, bapineuzumab and 
gantenerumab. Solanezumab, for example, is a humanized monoclonal anti-Ab antibody that 
targets and reduces plaque burden. However, in the case of solanezumab and other passive 
immunotherapeutics, there is so far no or little impact on the clinical outcomes of AD (Fu et 
al., 2010). 
 
1.11.3 Tau drug therapy 
The Inhibition of neurofibrillary tangles produced by aggregated Tau protein is another 
potential therapeutic approach for AD treatment. Inside neurons, tau tangles are likely to 
cause damage by inhibiting axonal transport (Mangialasche et al., 2010). Inhibition of Tau 
aggregation is therefore an attractive therapeutic strategy. Yet, attempts to produce an 
effective drug have been somewhat unsuccessful. Methylioninium chloride has been one of 
the most successful drugs, which showed promising results in phase 2 clinical trials (Wischik 
et al., 2008). A major drawback was that methylioninium chloride has multiple effects, such as 
on mitochondrial function by enhancing key biochemical pathways, which can lead to 
worsening AD pathology (Atamna et al., 2008). 
 
1.12 Peptide inhibitors against Ab 
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Small peptide molecules that have the potential to bind to Ab and prevent early formation of 
amyloid-b oligomers, provide a promising strategy which could halt or delay the progression 
of AD. Many of these peptides developed are not suitable for clinical trials, with only a few 
even progressing to animal testing (Taylor et al., 2010; Parthsarathy et al., 2013). Most of the 
peptide inhibitors are designed based on the findings that the internal sequence KLVFF (amino 
acids 16-20) is essential for binding interactions between Ab molecules (Tjernberg et al., 
1996). Several approaches were made, such as adding proline residues into the binding region 
of the amyloid peptide in order to induce destabilization or linking an oligolysine disrupting 
element to the Ab peptide binding sequence, all of which did not completely inhibit 
aggregation, but typically altered the aggregation kinetics (Ghanta et al., 1996). 
 
Austen et al. (2008) designed two peptide aggregation inhibitors that both contain the key 
region (KLVFF) required for Ab interactions between molecules. The peptides, known as OR1 
and OR2, also contained arginine (R) and glycine (G) residues on both ends to enhance 
solubility. OR1 has an amide group at the N-terminal and a carboxyl at the C terminal, whereas 
OR2 has an amide group at both terminals. Both inhibitors were shown to inhibit the formation 
of Ab fibrils, yet OR2 was proven more effective at inhibiting oligomers (Taylor et al., 2010).  
 
OR2 (RGKLVFFGR-NH2) inhibits the aggregation of Aβ into oligomers and fibrils, and blocks the 
toxic effects of Aβ on cultured cells. However, this peptide is sensitive to proteolysis, and was 
not designed to cross the BBB (Austen et al., 2008). To improve its stability, a retro-inverso 
version (RI-OR2) was made (Taylor et al., 2010), and this was enhanced further by the addition 
of a retro-inverted version of HIV-1 tat (TAT) to RI-OR2, producing RI-OR2-TAT (Parthsarathy 
et al., 2013). Following its peripheral injection, a fluorescein-labelled version of RI-OR2-TAT 
was found to cross the BBB and bind to the amyloid plaques present in the cerebral cortex of 
APPswe/PS1ΔE9 transgenic mice. Daily intraperitoneal (i.p.) injection of RI-OR2-TAT, for 3 
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weeks, into these mice resulted in substantial (25-45%) reductions in brain Aβ oligomer levels, 
amyloid plaque counts, oxidative damage, and inflammatory processes. However, RI-OR2-TAT 
inhibits Aβ aggregation only at relatively high concentrations (i.e. at a molar ratio of RI-OR2-
TAT:Aβ of 1:5 at best) and so its therapeutic potential is likely to be limited. 
 
1.13 The Blood Brain Barrier (BBB) 
An effective treatment for AD would most likely require the therapeutic agent concerned to 
be transported across the BBB, a metabolic and transport barrier that protects the brain from 
harmful stimuli. The BBB is comprised of brain capillary endothelial cells (BCECs) that are 
attached to each other through tight junctions, resulting in restricted paracellular transport 
(Bhowmik and Khan, 2015; Sanchez-Navarro et al., 2017). Degrading enzymes are also present 
at the BBB, which can destroy molecules during their attempted passage into the brain (Abbott 
et al., 2010). As a consequence, the BBB is permeable only to certain molecules, ions and 
macromolecules such as nutrients, that are either essential for brain function or a waste 
products. Only 2% of molecules with molecular weight of <500 Da can cross the BBB, and 
molecules greater than 1 kDa are unable to cross at all (Pardridge, 2007). There are specific 
mechanisms in place to mediate the transportation of these essential molecules, and these 
can be exploited for therapeutic drug delivery. Still, the BBB prevents access to the brain of 
around 98% of neurotherapeutics, thus  therapeutic potential remains limited. 
 
 
1.13.1 Early strategies for BBB transportation 
Passive diffusion permits the passage of some small lipophilic compounds across the BBB, such 
as certain amino acids, nucleosides, and small peptides. An early strategy utilised this simple 
mechanism by developing small lipophilic drugs that might pass through the endothelial cells. 
However, this excluded the vast majority of potential therapeutic molecules. A second 
approach was to develop small water-soluble drugs, in order to facilitate BBB transport via the 
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paracellular hydrophilic diffusion pathway. However, most of these potential molecules could 
not penetrate past the tight endothelial cell junctions (Hersh et al., 2016).  
1.13.2 Alternatives 
Intracerebral or intracerebroventricular injection of drugs provides a strategy that avoids the 
BBB, but these procedures are highly invasive, and so are not widely used. Drugs administered 
by any peripheral route (e.g. orally or by intravenous injection) will encounter the BBB 
(Agrawal et al., 2017). Alternative methods, such as bypassing the BBB by delivery through the 
olfactory region (e.g. as a nasal spray) have some potential (Li et al., 2012; Zheng et al., 2015; 
Illum, 2012). Another strategy looks to utilize existing active BBB transport mechanisms, 
namely carrier-mediated transcytosis (also known as transporter-mediated transcytosis), 
receptor-mediated transcytosis, cell-mediated endocytosis, and adsorptive transcytosis 
(Table 1.3) (Gao, 2016; Sanchez-Navarro et al., 2017). 
Transport mechanism Explanation Examples 
Carrier-mediated 
transcytosis 
Some essential materials required 
in the brain have specific 
transporters for active uptake 
across the BBB. Drugs can exploit 
these transporters for brain 
delivery. 
Glutathione  
(Gaillard et al., 2014). 
Choline  
(Li et al., 2011). 
Glucose 
(Xie et al., 2012). 
Receptor-mediated 
transcytosis 
Receptors on the BBB 
endothelium can bind specifically 
bind with corresponding ligands 
and trigger internalization. Drugs 
can incorporate these ligands, or 
their modified forms, for 
enhanced brain penetration. 
Transferrin receptor  
(Qian et al., 2002). 
Insulin receptor  
(Guo et al., 2012). 
Lactoferrin receptor  
(Fillebeen et al., 1999). 
Cell-mediated 
endocytosis 
Endocytosis into endothelial cells 
can deliver drugs across the BBB. 
This mechanism is almost 
exclusive to the action of CPPs 
which exhibit various features to 
trigger transportation, and they 
are often highly positively 
charged. 
TAT (Lindgren et al., 
2000). 
Penetratin 
(Derossi et al., 1994) 
Polyarginines 
(Futaki et al., 2001) 
 
Adsorptive transcytosis Adsorptive-mediated targeting 
utilizes a modified, positively 
charged biological 
macromolecule for interaction 
Cationized bovine serum 
albumin (CBSA) 
(Lu et al., 2005). 
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with the negatively charged BBB, 




(Guo et al., 2012) 
Table 1.3: Transport mechanisms for BBB transit and brain delivery. 
1.14 Cell penetrating peptides (CPPs) 
In the last 20 years, cell penetrating peptides (CPPs) have been identified, which are able to 
translocate across biological membranes including the BBB (Lindgren et al., 2000). They cross 
in a non-toxic manner, independent of membrane receptors and energy, which could reduce 
limitations of receptor saturation that have been observed with other methods. Most CPPs 
rely on positively charged amino acids interacting with the negatively charged membrane. 
Arginine, and to a lesser extent lysine, are particularly effective, as they form hydrogen bonds 
with the negatively charged phosphates, which may lead to internalization. CPPs with different 
properties vary in their internalization mechanisms (Table 1.4), but remain similar in their 
effective direct penetration of cell membranes. 
 
Among all CPPs, TAT protein is best described, and has been used successfully for delivery of 
liposome nanoparticles into the brain (Gregori et al., 2017). TAT triggers steps for non-specific 
endocytotic delivery due to ionic interactions between positive charges of the peptide and 
negative charges of the BBB (Vivès et al., 2003). Recent studies have utilised a retro-inverted 
version of TAT, where L-amino acids are replaced with D-amino acids, and the sequence is 
reversed. This reduces potential problems with TAT, such as protease degradation and poor 
bioavailability in vivo, but still maintains the ability for transport across the BBB (Parthsarathy 
et al., 2013). Alternative CPPs, such as polyarginines (e.g. octaarginine) and penetratin have 
also shown potential for the delivery of therapeutics directly to the brain in SAMP8 mice 







CPP Mechanism Origin References 
TAT Non-specific 
endocytosis 
HIV-1 Pathsarathy et al., 2013; 
Vivès et al., 2003 
Penetratin Endocytosis Antennapedia 
Drosophila 
melanogaster 
Derossi et al., 1994; 
Tseng et al., 2002. 
Pep-1 Pore formation Chimeric Henriques and Castanho, 
2008. 
Pep-7 Pore formation CHL8 peptide phage 
clone 
Gao et al., 2002 
pVEC Transporter mediated Murine endothelial 
cadherin 
Koren and Torchilin, 
2012. 
Transportan Endocytosis Galanin-mastoparan Pooga et al., 1998. 
Polyarginines Multiple mechanisms Chemically 
synthesised 
Futaki et al., 2001; 
Wender et al., 2000 
DPV1047 Energy dependent 
mechanisms, 





De Coupade et al., 2005 
MPG Pore formation HIV glycoprotein 
41/SV40 T antigen 
NLS 
Morris et al., 2008 








N terminus of 
unprocessed bovine 
prion protein 






Oehlke et al., 1997 
Bac 7 Likely non-specific 
endocytosis 
Bactenecin family of 
antimicrobial 
peptides 
Sadler et al., 2002 
C105Y Energy-independent 
process via caveolin- 
and clathrin-
independent lipid rafts 
a1-Antitrypsin Rhee and Davies, 2006 
PFVYLI Energy-independent 
process via caveolin- 
and clathrin-
independent lipid rafts 
Derived from 
synthetic C105Y 
Rhee and Davies, 2006 
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The therapeutic potential of liposomes was recognised shortly after their development by Alex 
Bangham in 1961, but have only more recently been considered as a suitable vehicle for 
delivery of drugs that act on the central nervous system (CNS) (Lai et al., 2013; Vieira and 
Gamara, 2016). Generally, liposomes are defined as auto-assembled spherical vesicles varying 
in diameter from a few nanometres (20 nm) to several micrometres (5 µm). They are made 
primarily from non-toxic lipids and phospholipids consisting of one or more bilayers that 
enclose a hydrophilic space (Vemuri and Rhodes, 1995) (Figure 1.5). They have been 
recognised as an attractive delivery system due to their chemical composition allowing easy 
modification of size, structure and composition. They are biocompatible and highly flexible, 
with the potential for carrying many different types of bioactive molecules, which typically are 
functionalised in the liposome core. Surface functionalisation can enhance diagnostic 
potential and drug delivery, giving liposomes unique advantages over alternative nanocarriers 
that have many limitations including poor delivery and limited therapeutics potential 





Figure 1.5: Simple schematic of a functionalised liposome. Liposome shows drug incorporated in the 
hydrophilic core, with PEG-Antibody surface functionalization. 
 
1.15.2 Composition and assembly 
The liposome size, as well as the lipid composition, affects their circulation in the bloodstream 
and uptake into the brain (Abra and Hunt, 1981; Harashima and Kiwada, 1996). Brain delivery 
requires liposomes to be roughly nano- or microsized and consist of one or more lipid bilayers 
surrounding an aqueous core. Only certain sizes will allow passage across the BBB for neuro-
therapy (such as in AD) and so small vesicles (<100 nm in diameter) are often preferred. There 
are studies, however, that have shown that liposomes from 100-140 nm have certain 
advantages, such as a longer half-life in blood circulation and avoidance of plasma proteins. 
Large nano-liposomes (250 nm in diameter) are cleared twice as fast as 100 nm liposomes 
(Fanciullino and Ciccolini, 2009). Yet, liposomes 100 nm and smaller have more limited storage 
capacity, leading to poor encapsulation efficiency (Allen, 1997). A consideration of size should 




Common materials used for liposome creation are a combination (one or more) of 
biodegradable and biocompatible lipids such as sphingomyelin, phosphatidylcholine and 
phosphoglycerates. These phospholipids are amphipathic in aqueous media, having two 
hydrophobic tails made from hydrocarbon chains and a hydrophilic phosphate head, and 
support the self-assembly of liposomes into spherical bilayers. Other properties can differ 
greatly with lipid composition, impacting the liposome rigidity or fluidity and charge of the 
bilayer. For instance, naturally sourced unsaturated phosphatidylcholine gives much more 
permeable and less stable bilayers, whereas the saturated phospholipid with long acyl chains 
forms an impermeable rigid bilayer (Gabizon et al., 1998; Allen et al., 1997). 
 
For the preparation of liposome self-assembled vesicles, the lipid composites are often 
dissolved in a solvent (e.g. chloroform) and evaporated to form a lipid film (Bangham method). 
Upon hydrating the lipid film, lipid bilayers are spontaneously produced, forming vesicles with 
a distinct inner space separated from surrounding space (Akbarzadeh et al., 2013). The 
hydrophobic and hydrophilic properties of the lipids incorporated impacts the shape of the 
vesicles and nature of the hydrophilic core. Therefore the lipid composition has an important 
impact on the function of the liposome vesicle product. As well as phospholipids, cholesterol 
is often an appropriate inclusion in liposomes. Cholesterol not only maintains the stability of 
membranes in vivo and in vitro, but also reduces membrane permeability, which overall alters 
the structure and function of the vesicle products (Masserini, 2013). The four hydrocarbon 
ring molecular structure of cholesterol makes it hydrophobic in nature, which results in its 
interaction with unsaturated lipids in the core of the membrane. This causes a kink to form in 
the chain and allows phospholipids to take up more space in the bilayer, producing a less 





Figure 1.6: Interaction of cholesterol with unsaturated lipids. Cholesterol integrates in the core of 
the lipid bilayers, causing a kink to form in the phospholipid (e.g. sphingomyelin) hydrocarbon tails. 
The cholesterol situates parallel to the phospholipids, and the hydroxyl group (orange) interacts 
with the phospholipid heads (red). 
 
There are multiple preparation methods for producing nanoliposomes. The appropriate 
method is dependent on several factors. These include the physiochemical characteristics of 
the liposome or the drug to be loaded (e.g. the hydrophilicity/hydrophobicity or the 
concentration of the loaded substance), the medium in which  liposomes are dispersed (e.g. 
phosphate buffered saline (PBS)), the application and delivery of the liposomes and additional 
factors for liposome production for large scale clinical practice (Gómez-Hens and Fernández-
Romero, 2006; Wagner and Vorauer-Uhl, 2011). The most commonly used technique is likely 
to be the Bangham or thin-film hydration method, which involves the dissolution of lipid in an 
organic solvent, evaporation to form a film and hydration in aqueous solution. A drug can be 
trapped in the hydrophilic core or in the lipophilic bilayers, depending on the properties of the 
therapeutic molecule. The disadvantage, however, is a poor encapsulation efficiency of water-
soluble drugs (~10%) (Bangham et al., 1965; Bozzuto and Molinari, 2015). 
 
Alternative methods such as reverse-phase evaporation and solvent-injection provide higher 
encapsulation efficiency than the Bangham method, yet after having dissolved the lipids in the 
solvent, it is more challenging separating the solvent from the liposome product. The 
detergent-depletion method involves hydration of a lipid film with a detergent, but is rarely 
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used as it has both poor encapsulation efficiency and a long preparation period (Deamer and 
Bangham, 1976; Szoka and Papahadjopoulous, 1978; Lasch et al., 2003). However, the 
Bangham method remains one of the most widely used techniques. The Bangham method 
requires additional processes after hydration in aqueous media, as the standard method 
producing large, non-homogenous vesicles that require a freeze and thaw, sonication and 
extrusion processes in order to produce homogenous liposomes of controlled sizes. 
 
1.15.3 Classification 
Liposomes are classified on their size and lamellarity as well as their preparation method and 
composition. Liposome size is tailored for its therapeutic application and is important for the 
success of the nanocarrier. For example, only certain sizes will allow passage across the BBB 
for neuro-therapy (such as in AD) and so small vesicles (less than 100 nm) are often preferred. 
 
Liposomal size is linked to the specific preparation method used (described above) and the 
subsequent lamellarity of the liposome. Lamellarity refers to the number of lipid bilayers in 
liposomes, and is an important method of classification. Liposomes can either form 
unilamellar vesicles (ULVs) or multilamellar vesicles (MLVs) (Figure 1.7) depending on the 
preparation method and any other additional processes conducted. ULVs only have one 
bilayer with diameter ranging from a few nm to 400 nm. They enclose a large hydrophilic core 
and so their application is to encapsulate hydrophilic drugs. ULVs are subcategorised into large 
unilamellar vesicles (LUVs) with a diameter of 100 nm and more, and small unilamellar vesicles 
(SUVs) with a diameter of 20-100 nm (Masserini, 2013). MLVs are much larger (1-5 µm) and 
have two or more concentric lipid bilayers. They preferentially entrap lipophilic drugs, due to 
their large area of lipophilic bilayer (Immordino et al., 2006;). The Bangham preparation 
method produces large non-homogenous MLVs, and it is the additional sonication and 




Figure 1.7: Schematic illustration of MLVs and ULVs. MLV shows two lipid bilayers with a small 
aqueous hydrophilic core, suited for lipophilic drug entrapment. ULVs are subcategorised into LUVs 
and SUVs. LUVs (100 nm diameter and more) have a large enclosed aqueous core, suitable for 
hydrophilic drug incorporation. SUVs (20-100 nm) are similar LUVs, but suited to applications 
requiring small nano-carriers. 
 
1.15.4 Stability and modification 
One essential function of the lipid bilayer of the liposome product is that their physiological 
composition facilitates numerous modifications, in comparison to other nano-carriers. These 
modifications can improve stability, facilitate transport into cells, or across the BBB, and allow 
specific molecular targeting for therapeutic benefit. 
 
1.15.4.1 Stealth liposomes 
Although liposomes are considered harmless to the human body, they are detected by the 
mononuclear phagocytic system (MPS). Liposomes are covered in plasma proteins (e.g. 
fibrinogen, immunoglobulins and complement proteins) during blood circulation, so that a 
‘protein corona’ is formed around them. This leads to the activation of phagocytic systems and 
removal of liposomes from the bloodstream (Palchetti et al., 2016), creating problems with 
their in vivo stability. 
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In order to improve stability, methods have been developed to improve the pharmacokinetic 
profile of liposomes to allow longer time-periods in circulation. Polyethylene glycol (PEG) or 
other polysaccharides are coated on the liposomes or incorporated into the lipid components 
of the bilayer, producing these so-called ‘stealth’ liposomes. PEG has high hydration capacity 
and this increases hydrodynamic volume and allows the formation of a water cloud around 
the polymer. Any hydrophilic molecule bound covalently to PEG also exhibits these properties, 
providing increased solubility, and resistance to interaction with plasma proteins. 
Subsequently, PEGylated liposomes in circulation are less prone to formation of a protein 
corona, allowing dramatically improved circulation times (Veronese and Mero, 2008). 
 
1.15.4.2 BBB delivery 
Possible mechanisms for the transport of liposomes across the BBB have been highly debated 
(Agrawal et al., 2017). An initial theory was that the phospholipid bilayer of the liposomes on 
its own might facilitate transportation across various biological membranes, including the BBB, 
but this simple mechanism proved to be ineffective. A strategy with increasing interest 
involves the use of CPPs to directly penetrate the BBB endothelium increase liposome 
transport to the brain. Classical methods to enhance transport instead utilize existing BBB 
active transport mechanisms (Figure 1.8). 
 
In order to enhance BBB transportation, liposome surface modification can use two different 
techniques: (a) ligands are attached onto liposomes during preparation, or (b) ligands are 
covalently conjugated to the liposome surface post-preparation. The attachment during 
preparation involves incorporating the ligand into lipid mixture before lipid extrusion, and will 
produce varied ligand binding efficiency. Covalent conjugation is often carried out with ligands 
that contain thiol groups to react with maleimide or bromoacetyl anchors, forming thioether 
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or disulphide bonds (Schuber et al., 2007). A second common conjugation attaches ligands to 




Figure 1.8: Promising liposomal BBB transport mechanisms. Receptor-mediated transcytosis 
exploits receptors highly expressed at the BBB (e.g. transferrin receptor). Receptor ligand binding 
triggers internalization and brain delivery. A relatively new mechanism, direct penetration, involves 
internalization primarily exhibited by CPPs (e.g. TAT). Positively charged amino acids (+++) permit 










1.15.4.3 AD targeting 
It is likely that the accumulation and aggregation of Ab in the brain has an important role, 
directly or indirectly, in the induction of synaptic damage and memory deficits in AD (Hardy 
and Allsop, 1991; Hardy and Selkoe, 2002). The accumulation of Ab oligomers or fibrils may be 
caused by overproduction, inefficient clearance from the brain, or by a combination of both 
of these. Effective therapeutic molecules can have an impact on one of these mechanisms to 
reduce Ab burden. Many of these molecules on their own have low uptake across the BBB, 
but their incorporation into a multi-functionalised liposomal system, with molecules that 
enhance BBB transport, can help to resolve this problem and allow effective targeting to Ab 
(Figure 1.9).  
 
 
Figure 1.9: Functionalised Liposome AD targets. Post BBB transport, functionalised liposomes 
specific for Ab or Tau will respectively accumulate at Ab plaques and neurofibrillary Tau tangles. 
Encapsulated drugs can be released for therapeutic treatment. 
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Various types of therapeutic agents can be attached to the surface of the liposomes. These 
various configurations can be combined to give a targeted multi-drug delivery system, which 
is particularly relevant for treatment of AD since it is a multifactorial disease (Noble et al., 
2014). Theoretically, anti-Ab and anti-Tau molecules can be integrated into one liposome 
delivery system in order to produce a treatment more potent than current therapies. 
 
1.15.5 Peptide Inhibitor Nanoparticles (PINPs) 
A small peptide, named OR2 (RGKLVFFGR-NH2), inhibits the aggregation of Aβ into oligomers 
and fibrils, and blocks the toxic effects of Aβ on cultured cells (Austen et al., 2008). To improve 
its stability, a retro-inverso version (RI-OR2) was made (Taylor et al., 2010), and this was 
enhanced further by the addition of a retro-inverted version of TAT to RI-OR2, producing 
RI-OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH2) (Parthsarathy et al., 2013). However, RI-OR2-TAT 
inhibits Aβ aggregation only at relatively high concentrations, (i.e. at a molar ratio of RI-OR2-
TAT:Aβ of 1:5 at best) limiting its therapeutic potential. 
 
In order to improve RI-OR2-TAT further, it was attached to the surface of stealth liposomes by 
covalent linkage to the PEGylated lipid, via an additional cysteine residue on the peptide, to 
produce ‘peptide inhibitor nanoparticles’ (PINPs) (Gregori et al., 2017) (Figure 1.10). The 
presence of the liposome carrier greatly improves the potency of RI-OR2-TAT, so that a molar 
ratio of 1:2000 of liposome-linked inhibitory peptide to Aβ now gives ~50% inhibition of Aβ 
aggregation. This great increase in potency could be due to a multivalent effect. Many copies 
of the RI-OR2-TAT decorate each liposome, which should allow the simultaneous interaction 
of multiple inhibitory peptides with any multimeric form of Aβ, so increasing efficiency as an 
aggregation inhibitor. EM studies (Sherer et al., 2015) have shown that PINPs can attach 
themselves to the free ends of amyloid fibrils, apparently terminating fibril growth, and 
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preventing the formation of Aβ oligomers (the free ends of fibrils act as ‘factories’ for 
generation of oligomeric Aβ) (Eisenberg and Jucker, 2012).  
 
Studies in transgenic mice have shown that peripheral injection of PINPs protects against 
memory loss in TG2576 mice (Gregori et al., 2017). The TAT region of the inhibitory peptide 
facilitates brain penetration, with a brain:blood ratio of around 50% being achieved shortly 
after intravenous (i.v.) injection. However, most of the dose accumulates in peripheral tissues, 
such as lungs, liver, and spleen, most likely due to clearance of liposomes via the 
reticuloendothelial system, and so it is possible that the ‘sink’ effect could explain some of the 
in vivo properties of PINPs. The effectiveness of these PINPs could be improved in the future 





Figure 1.10: Targeting strategy with PINPs. PINPs transport across the BBB by non-specific 
endocytosis, triggered by positively charged TAT interaction with the negatively charged 
membrane. RI-OR2-TAT inhibitor acts to prevent the aggregation of Aβ into oligomers and fibrils. 
 
1.15.6 Antibody loaded liposomes with RI-OR2-TAT surface modification 
In the current study, RI-OR2-TAT has been attached onto liposomes, loaded with monoclonal 
antibodies. Anti-Aβ  (van Dyck, 2018) and anti-Tau (Yanamandra et al., 2017) antibodies have 
been developed with the therapeutic potential to treat AD. To improve plain and RI-OR2-TAT 
liposomes for AD therapy, a good strategy looks to load them with anti-Aβ and anti-Tau 
antibodies, which can then be analysed to determine their therapeutic potential for future 
use. Liposomes have widely been used for antibody delivery, but studies are limited for AD 
treatment and even fewer have looked to incorporate antibodies into the hydrophilic core, 
and instead have involved surface attachment. Rotman et al (2015) utilised G-Technology for 
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the delivery of an anti-amyloid antibody fragment into APPswe/PS1dE9 double transgenic mice, 
which successfully passed the BBB (Rotman et al., 2015). The current study will utilise the 
Bangham method to observe the uptake into neuronal cells rather than transport across the 
BBB. The principles of the study remain the same, to evaluate the potential for the use of 
antibody incorporated liposomes for AD therapy, by analyzing the ultrastructure, stability and 
cell penetration efficacy. 
 
1.16 Scope of the Thesis 
The aim of this project is to investigate the incorporation of antibodies into the hydrophilic 
core of liposomes. This involves: 
 
1. Development and refinement of antibody encapsulation in liposomes, and to 
determine which size liposome is appropriate (50, 100 or 200 nm). 
2. Characterise the impact of antibody incorporation on size and shape of the liposomes. 
3. Evaluate their ability to penetrate SH-SY5Y neuroblastoma cells, using RI-OR2-TAT for 
cell penetration, giving an insight into whether these types of liposomes can be used 


















CHAPTER TWO - Materials and Methods 
 




Sigma – Aldrich (Poole, UK) 




VWR Chemicals (Leighton Buzzard, UK) 
Ethanol 70% Fisher Scientific (Loughborough, UK) 
LabAssayTM Phospholipid Wako chemicals (Richmond, USA) 
 
Table 2.2 Lipids 
Name Abbreviation Producer 
Cholesterol (plant derived) CH Avanti Polar Lipids Inc., 
U.S. 











BDP-Chol (Bodipy) Avanti Polar Lipids Inc., 
U.S. 
 
Table 2.3 Antibodies 
Antibody Producer 
Immunogold conjugate EM goat anti-
fluorescein: 10nm  
BBI solutions (Cardiff, UK) 
Goat Anti-Fluorescein antibody (Biotin) 
 
Abcam (Cambridge, UK) 
Anti-Rabbit IgG F(abʹ)2-Peroxidase antibody 
produced in goat  
 
Sigma – Aldrich (Poole, UK) 
b-Actin Rabbit mAb (Alexa Fluor 594 
Conjugate)  
Cell Signalling Technology 
(Hertfordshire, UK) 
 
Table 2.4 Peptide Inhibitor 
RI-OR2-TAT-Cysteine ((Ac- 
rGffvlkGrrrrqrrkkrGyc-NH2) 




2.1 Buffered solutions 
Phosphate buffered saline (PBS) was made with 5 PBS tablets (Sigma – Aldrich) dissolved in 
500 mL distilled deionized water to produce 500 mL stock PBS with pH ~7.3 at 25°C (10mM 
phosphate Buffer and 150mM NaCl). Stock was autoclaved to sterilise for further use. 
 
2.2 Development of RI-OR2-TAT antibody loaded liposomes 
2.2.1 Preparation of lipids 
Sphingomyelin and Cholesterol were weighed at 47.5 molar % and mixed in a glass vial. 5 molar 
% DSPE – PEG – MAL was then added to the two lipids and the lipid mixture was dissolved in 
chloroform. The liposome suspension contains a 1:1 molar ratio of sphingomyelin to 
Cholesterol, with 5% molar DSPE – PEG – MAL. Using 5% DSPE – PEG – MAL in theory allowed 
~2.5%  entrapped in the liposome and ~2.5% attached to the surface. 
 
2.2.2 Hydration of lipid film 
Lipid mixture was dissolved in chloroform, and evaporated under nitrogen stream (~200 bar 
pressure) in a round bottom tube, rotated manually every few minutes until chloroform was 
evaporated and a thin lipid film was created (~30 minutes). At this point, antibody  (~10 µL per 
1 mL sample) was directly added to the lipid film (for liposomes with antibodies incorporated) 
and incubated at room temperature (RT) for 3 mins. All liposome samples were then 
resuspended in filtered PBS, pH 7.3 at 5mM lipid. The hydrated lipid film was vortexed to 
detach the lipid from the glass vial and stored overnight at 4°C. Lipids were alternatively 






2.2.3 Antibody incorporation 
Antibodies were added after rehydration of the lipid film. The methodology for antibody 
incorporation was later refined, and antibodies were applied directly to the lipid film before 
resuspension (as described above). 
 
2.2.4 Freeze and thaw process 
Rapid freezing and thawing is necessary to produce nano-liposomes smaller than 200 nm in 
diameter. It also produces unilamellar vesicles from multilamellar vesicles. (Akbarzadeh et al., 
2013). The 4 mL solution with lipid film was shaken, vortexed and then split into 1 mL aliquots 
in Eppendorfs. Each tube containing the lipid suspension was frozen for 15 secs in liquid 
nitrogen and thawed using a heating block at 42°C for 3 mins. This process was repeated for 5 
cycles per 1 mL sample. 
 
2.2.5 Sonication 
The lipid suspensions were then sonicated for 5 minutes at 45°C in an ultrawave bath 
sonicator. 
 
2.2.6 Liposome extrusion 
The Avanti Lipids mini-extruder was used for the extrusion of unilamellar nano-liposomes. 
After assembly, the system was checked for leaks by pumping one passage of filtered PBS 
through the membrane. This also moistened the membrane for enhanced liposome passage. 
For this process, one Hamilton syringe was filled and rinsed with distilled water and then 
filtered PBS and then pumped through the membrane to the other syringe and discarded. 
After the system has been checked for leaks, 1 mL liposome suspension was added to a 
Hamilton syringe which was positioned in the extruder, and passaged slowly through the 
 40 
system. 11 passages were conducted for each sample. This was repeated for polycarbonate 
membranes with pore sizes of 50 nm, 100 nm and 200 nm to make different sized liposomes. 
 
 
Figure 2.1: Construct of the Avanti lipids mini extruder. The schematic shows labelled parts and 
assembly (Avantilipids.com). 
 
2.2.7 The attachment of RI-OR2-TAT 
The peptide inhibitor RI-OR2-TAT was covalently bound to the surface of liposomes by ‘click 
chemistry’. This requires the addition of a cysteine residue, forming RI-OR2-TAT-Cys (Ac- 
rGffvlkGrrrrqrrkkrGyc-NH2). This peptide inhibitor was added to the extruded liposomes at 2.5 
molar % of the total liposome suspension and incubated at 37°C for 2 hours. The inhibitor 
covalently bound to the DSPE – PEG – MAL, which is statistically at 2.5 molar % on the liposome 
surface (5% total, 2.5% internalised and 2.5% on the surface). Washing steps were taken to 
remove any unbound peptide or antibody that was not incorporated inside the vesicles. The 
mixture was centrifuged at 50k RPM for 1 hour at 4°C (70.1 Ti rotor). The supernatant was 
discarded and the pellet was resuspended in 1 mL filtered PBS and vortexed to mix the 
solution. Liposomes produced were stored at 4°C.  
 
The above procedure can also be conducted to produce antibody loaded PEGylated liposomes. 
For this, the above protocol was followed without the inclusion of the RI-OR2-TAT attachment. 
Similarly, plain PEGylated liposomes were made without antibody incorporation steps. 
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Fluorescent liposomes were also produced following the same procedure, using a different 
composition of lipids. Fluorescent cholesterol is included at 1% of the total cholesterol (0.475 
molar % of the total liposome solution). During the preparation of fluorescent liposomes the 
whole procedure was carried out in a darkened room because fluorescent cholesterol is 
sensitive to light. 
 
2.3 Dynamic Light Scattering (DLS) 
Analysis of liposome size, polydispersity index (PDI) and zeta potential was obtained by DLS 
using a Zetasizer Nano ZS instrument (Malvern Instruments Ltd., U.K.) at 25°C. Small samples 
(~40 μL) were added to disposable micro cuvettes, and larger samples (~1 mL) were added to 
disposable cells, both of which were suited for the instrument. Photon Correlation 
Spectroscopy determined the particle size and PDI by measuring Brownian motion of the 
particles in the samples. This worked on the theory that movement speed of liquid is 
dependent on the size of the particle. Backscatter was measured at 175°. Data was obtained 
in triplets and presented as a mean of these repeats. Specialised disposable cuvettes were 
used to measure zeta potential (Malvern Instruments Ltd., U.K.). 
 
2.4 Phospholipid WAKO assay (Choline oxidase-DAOS method) 
The concentration of liposomes was performed using the Phospholipid B WAKO assay kit. It 
worked on the basis that the quantification of sphingomyelin can be measured by an 
enzymatic reaction using N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5- dimethoxyaniline (DAOS) 






2.4.1 Preparation of solutions 
The assay used three standard phospholipid concentrations, which was extended to five by 
further dilutions with deionized water (Table 2.5). 50 mL Chromogenic substrate were 







0.375 1/8 2µL 
0.75 1/4 2µL 
1.5 1/2  2µL 
3 Undiluted 2µL 
5.961 Undiluted 4µL 
 
Table 2.5: Preparation of phospholipid standards for the WAKO assay. 
 
2.4.2 Chromogenic assay 
Assay was completed using a clear 96 well plate (ThermoFisher) and all samples were 
performed in triplicates. Standard samples volumes were added to wells according to Table. 2 
µL of each lipid or liposomes suspension was added to each well. Chromogenic substrate was 
added to each well to produce a final volume of 300 µL. The plate was shaken well and then 
incubated at 37°C for 5 mins. Absorbance was measured at 600 nm on a plate reader. 700 nm 




2.5 Transmission Electron Microscopy (TEM) 
PEGylated liposomes of three sizes (50 nm 100 nm and 200 nm), antibody loaded liposomes 
and liposomes with attached RI-OR2-TAT inhibitor were prepared and examined by TEM. 
 
2.5.1 Preparation of  liposomes on TEM grids 
The heavy metal phosphotungstic acid (2%) (PTA) was used for liposome staining. For 
preparation, 0.1 g PTA stock was dissolved in 4 mL distilled H2O (dH2O). The solution was 
vortexed for 1 min and mixed with a magnetic stirrer for 5 mins, then filled to 5 mL with dH2O. 
Liposomes were pipetted onto Formvar copper grids (G2004, 400Thin, copper 3.05 mm – 
ATHENE). ~20 μL of liposome solution (1 mM) was added to the shiny copper side of the grid 
for 2 mins so that the liposomes were adsorbed. The surplus was removed with filter paper. 
~5 μL of 2% PTA was added and left for 2 mins. Filter paper was again used to remove the 
surplus and the samples were left to dry at RT. Grids were stored in a glass petri dish until they 
were ready for further use. Samples that incorporated gold conjugates did not require PTA 
staining, and so the procedure was conducted in absence of PTA incubation.  
 
2.5.2 TEM and image processing 
The film plates (Kodak Electron Microscopy Film 4489, Agar scientific, UK) used for image 
capture and underwent dehydration using a vacuum desiccator before capture. The TEM (JEOL 
JEM 1010) was then used for the capture of images, and the exposed film plates were stored 
in complete darkness until further use. Developer was prepared at approximately 20°C and 
consisted of 1 part developer to 4 parts distilled water. In a dark room, the films were 
transferred to a black developing rack, then immersed in developer (Ilford phenisol developer) 
contained in a black vessel and left for 4 mins. The rack was washed, and then moved into a 
container with fixation solution (Ilford hypam fixer) for 4 mins. At each stage, the developing 
rack was agitated every 1 min to allow effective development of films. The rack was then 
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transported out of the dark room, and placed in a water bath for 2 hours with a fresh water 
flow. ~5 drops of wetting agent (Kodak foto – flo) was added 5 mins prior to the end of the 2 
hour water bath incubation. Afterwards, racks were air-dried overnight. Images were scanned, 
then processed using TEM Analysis software and edited using Image J and Microsoft Office. 
Some images were alternatively captured with a TEM digital camera (AMT Nano sprint 500 
sCMOS) and analysed with Advanced Microscope Techniques (AMT) software (AMT Capture 
Engine). 
 
2.6 Cell penetration assay 
In order test the ability of prepared liposomes to penetrate cells, a cell penetration assay was 
designed using various liposome modifications and a neuroblastoma (SH-SY5Y) cell line. Cells 
were grown in Dulbecco’s Modified Eagle Medium and F12 (DMEM/F12 – 1:1 ratio), containing 
10% Fetal Calf Serum and 1% antibiotics (Streptomycin and Penicillin – 1:1 ratio) and grown at 
37°C and 5% CO2.  
 
2.6.1 Cell maintenance 
Cells were grown as above and the medium was changed every 3-7 days and cells were split 
at ~80% confluency. For splitting, cells are detached with trypsin by incubation at 37°C and 5% 
CO2, centrifuged at 1000 RPM for 7 mins at 25°C and the pellet was resuspended in growth 
medium as described, and transferred into a new flask. 
 
2.6.2 Immunostaining of SH-SY5Y cells 
Liposome cell penetration was studied by immunostaining SH-SY5Y cells. Fluorescent (BODIPY) 
cholesterol  and b-Actin Rabbit mAb (Alexa Fluor) were used for fluorescence observation. 
Cells were grown in 6 well plates with DMEM growth medium. Cover slips were incubated in 
the cell culture for 24 h at 37°C and 5% CO2, where cells grew on the surface of the cover slips. 
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Liposomes of varying concentrations  (50 μM, 100 μM and 200 μM) and properties were added 
to each well and incubated for 2 h at 37°C and 5% CO2. A spiking solution of 2% PFA in PBS was 
prepared into each well and incubated at RT for 2 minutes. The cover slips were then washed 
and incubated with 4% PFA at RT for a further 20 minutes. 3 μL antifade mountant with DAPI 
(Invitrogen – Gibco®) was added to glass slides. Coverslips were removed from the wells and 
placed cell slide down onto the Fluoroshield and allowed to dry at RT for 24 h. Samples were 
examined under confocal microscope (LSM 510 – Laser Module – Zeiss). 
 
2.7 Ethics and data analysis 
2.7.1 Ethical consideration 
All experimentation was submitted to the University of Lancaster research and ethical body. 
Research undertaken was considered to be acceptable and was therefore approved. 
 
2.7.2 Statistical analysis 
Microsoft excel and SPSS statistical software was used for data analysis, evaluation and the 
production of figures and tables. A variety of analytical tests were used for analysis, including 
Paired and un-paired T-tests and one way ANOVA. Each were used appropriately for different 












CHAPTER THREE – Dynamic Light Scattering Results 
 
3.1 Characterisation of liposomes by size 
Dynamic light scattering (DLS) was used to assess the diameter, polydispersity and stability of 
each liposome size (50 nm, 100 nm and 200 nm) and type (Table 3.1) produced according to 
protocol (Zetasizer Nano ZS, Malvern Instruments Ltd., U.K.). Standard gold nanoparticles of 
distinct sizes were also examined to calibrate the system for liposome measurements. Table 
3.1 shows the abbreviations used for each type of liposomes, which are consistent throughout 
each section of the thesis. 
 
 Abbreviation Liposome modification 
PEG-NLs Plain liposomes of sphingomyelin (SM) and cholesterol (CH), with the addition of 
DSPE-MAL-PEG. 
AB-NLs PEGylated liposomes with antibodies incorporated in the hydrophilic core. 
RI-OR2-TAT-NL PEGylated liposomes with attached RI-OR2-TAT peptide inhibitor. 
RI-OR2-TAT+AB-NL PEGylated liposomes with attached RI-OR2-TAT and incorporated antibodies. 
 
Table 3.1: The different types of liposomes produced for experimentation. All of the liposomes 









3.2 Standard gold nanoparticles 
Four distinct sizes (20 nm, 40 nm, 60 nm and 80 nm) of nanogold were used for calibration. 
Each size of gold particle was examined at the most suitable dilution. Each dilution was 
prepared using filtered Phosphate Buffered Saline (PBS). The optimal 80 nm nanogold dilution 
of 1:250 gave mean size and standard deviation (±SD) of 79.09 ± 28.68 nm. The 60 nm 
nanogold dilution of 1:250 gave mean size of 57.20 ± 20.29 nm. The 40 nm nanogold dilution 
of 1:500 gave mean size of 40.39 ± 14.48 nm. The 20 nm nanogold dilution of 1:500 gave mean 
size of 23.59 ± 8.996 (Figure 3.1).  
 
PDI is a measurement of the polydispersity, performed by DLS, that was observed to 
determine the size distribution of the gold standards. High PDI can be a result of a wide 
distribution of sizes or multiple peaks in one population. Gold nanoparticles of 80 nm, 60 nm, 




Figure 3.1: Average diameter of gold nanoparticles at optimal dilutions. Bars show mean 
diameter ± SD at optimal dilutions of different gold nanoparticles. The larger gold nanoparticles 



















Figure 3.2: Size distribution of gold nanoparticle standards at optimal dilutions. The red, blue, 
pink and green lines represent 20 nm, 40 nm, 60 nm and 80 nm gold nanoparticles at optimal 
dilutions. The PDI of the particles is higher than expected, with many overlapping size distributions. 
 
3.3 PEGylated liposomes 
PEG-NLs are composed of sphingomyelin (SM), cholesterol (CH) and DSPE-MAL-PEG in a molar 
ratio of 47.5% SM, 47.5% CH and 5% PEG. PEG allows the formation of a lipid molecule with 
increased stability in blood circulation in order to maximise brain delivery of incorporated 
therapeutics (Wang et al., 2012). Optimum dilutions of PEGylated liposomes were determined 
by analysis of the gold nanoparticle results. Three sizes (200 nm, 100 nm and 50 nm) of 
liposomes were produced and examined by DLS. In the case of 200 nm PEGylated liposomes, 
a 1:125 dilution gave mean size of 213.50 ± 9.30 nm. The dilution of 100 nm liposomes gave 
mean size 180.30 ± 5.16 nm. The dilution of 50 nm liposomes gave mean size of 49.51 ± 0.49 
nm (Figure 3.3). 
 
 The 200 nm PEG-NLs had a PDI of 0.373. They were widely distributed with a broad peak 



















Colloidal gold diameter (nm)
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PDI of 0.44, with a fairly broad peak at 164.2 nm and a tighter peak at 4460 nm. The 50 nm 
PEG-NLs had a PDI of 0.282, with distinct peaks of 220.70 nm and 50.75 nm. 
 
Figure 3.3: PEG-NLs at optimal dilutions. Bars show mean diameter ± SD (n=3) at optimal dilutions 
of different sized PEG-NLs . Results were significant at a 5% confidence level (P=0.0034). 
 
 
Figure 3.4: Size distribution of PEG-NLs. The red, blue and pink lines represent 50 nm, 100 nm and 
200 nm liposomes at optimal dilutions. 200 nm is widely distributed and highly polydisperse. 50 nm 
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3.4 Antibody loaded liposomes 
AB-NLs are composed of SM, CH and DSPE-MAL-PEG in a molar ratio of 47.5%, 47.5% and 5%. 
During liposome preparation,  b-Actin Rabbit mAb Alexa Fluor 594 Conjugate (Alexa Fluor) was 
added to the lipid film before rehydration and incubated at RT for 3 mins. Optimal dilutions 
for loaded liposomes were determined from the PEGylated liposomes results. 200 nm and 100 
nm antibody loaded liposomes were prepared and compared to plain PEGylated liposomes.  
 
The 200 nm antibody loaded liposomes 1:125 dilution gave a mean diameter of 213.5 ± 9.68 
nm. They had a PDI of 0.362 and were distributed as one distinct peak (Figure 3.5 and 3.6). 
The 100 nm antibody loaded liposomes 1:500 dilution gave a mean size of 196.7 ± 9.51 nm. 
They had a PDI of 0.362 and were distributed as one distinct peak (Figure 3.7 and 3.8). 
 
 
Figure 3.5: PEG-NLs and AB-NLs (200 nm). Bars show mean diameter ± SD (n=3) at optimal 


















Figure 3.6: Size distribution of PEG-NLs and AB-NLs (200 nm). The red and blue line represent PEG-




Figure 3.7: PEG-NLs and AB-NLs (100 nm). Bars show mean diameter ± SD (n=3) at optimal 






































Figure 3.8: Size distribution of PEG-NLs and AB-NLs (100 nm). The red and blue line represent PEG-
NLs and AB-NLs respectively. There was no significant difference between distribution. 
 
 
3.5 RI-OR2-TAT and RI-OR2-TAT+AB modified liposomes 
Antibody loaded liposomes were prepared as before, with additional attachment of RI-OR2-
TAT-Cysteine ((Ac- rGffvlkGrrrrqrrkkrGyc-NH2) peptide inhibitor. The RI-OR2-TAT attaches to 
liposomes via click chemistry, and has a TAT CPP sequence capable of enhancing cell 
internalization.  Liposomes (100 nm in diameter) were produced with RI-OR2-TAT and 
antibody (Alexa Fluor) loaded RI-OR2-TAT modification. A diameter of 100 nm (1:500 dilution) 
was used based on previous antibody loaded liposome results and the fact that 100 nm 
liposomes are stable in blood circulation, suitable for BBB transportation and for neuronal cell 
uptake. These RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs were compared with PEG-NLs and AB-
NLs. 
 
Figure 3.9 and 3.10 show the DLS results of these modifications. The RI-OR2-TAT+AB-NLs 
dilution gave a mean diameter of 363.4 ± 60.72 nm. They had a PDI of 0.469 and were 
distributed with two distinct peaks. RI-OR2-TAT-NLs gave a mean diameter of 279.2 ± 46.62 





















Figure 3.9: Diameter of various liposome modifications (100 nm). Bars show mean diameter ± SD 
(n=3) at a 1:500 dilution of RI-OR2-TAT+AB-NLs, RI-OR2-TAT-NLs, AB-NLs and PEG-NLs. The RI-OR2-




Figure 3.10: Size distribution of various liposome modifications (100 nm). The red, blue, pink and 
yellow line represent PEG-NLs, AB-NLs, RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs respectively at a 
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CHAPTER FOUR – Transmission Electron Microscopy Results 
 
4.1 The characterisation of liposomes by Transmission electron microscopy (TEM) 
The morphology and ultrastructure of four types of nanoliposomes was investigated using 
TEM. This powerful imaging tool cannot determine behavioural or chemical differences 
between NL, AB-NL, RI-OR2-TAT-NL, RI-OR2-TAT+AB-NL but will highlight differences between 
their size and shape. TEM is additionally able to identify an antibody that is conjugated with a 
heavy metal, e.g. gold. A key structural property TEM can reveal is the lamellarity of liposomes. 
Freeze thaw and sonication steps in the preparation method aid the formation of unilamellar 
rather than multilamellar vesicles, which are desirable for therapeutic application. However, 
additional modifications (such as RI-OR2-TAT attachment) may also impact on vesicle 
lamellarity. TEM samples were prepared using 3 mM liposomes diluted with filtered PBS. 
Overall, this was an appropriate concentration, yet occasionally samples were too dilute with 
few vesicles present. Regardless of this, all samples had a tendency to clump. 
 
4.2 The characterisation of  PEG-NLs 
PEG-NLs were prepared and negatively stained with phosphotungstic acid (PTA) for 
visualisation. Micrographs of 50 nm, 100 nm and 200 nm NLs  were prepared for TEM analysis. 
 
4.2.1 PEG-NLs - 50 nm 
The following negative staining micrographs include liposomes of 50 nm in diameter. 
Liposomes were subjected to freeze and thaw and bath sonication during their preparation in 
expectation to produce unilamellar vesicles. As shown, vesicles were all regular in size and 





Figure 4.1: 50 nm PEG-NLs in filtered PBS. The liposomes are seen as round in shape with diameter 
close to 50 nm. Arrow shows unilamellar structure and dashed line shows the single layer at higher 
magnification. Scale bar = 50 nm. 
 
4.2.2 PEG-NLs - 100 nm 
The following negative staining micrographs show liposomes of 100 nm in diameter. 
Liposomes were subjected to freeze and thaw and bath sonication during their preparation in 
expectation to produce unilamellar vesicles. Liposomes were fairly irregular in shape and 





            
Figure 4.2: 100 nm PEG-NLs in filtered PBS. The liposomes are seen as round in shape and vary in 
diameter with some close to 100 nm. Dashed line shows a liposome 100 nm in diameter at a higher 



















4.2.3 PEG-NLs - 200 nm 
The following negative staining micrographs include liposomes of 200 nm in diameter. 200 nm 
liposomes were not subjected to freeze and thaw and bath sonication during their 
preparation, as it decreases the diameter of produced vesicles. 
 
                               
Figure 4.3: 200 nm PEG-NLs in filtered PBS. The liposomes are seen as round in shape and vary in 
diameter with some close to 200 nm. Scale bar = 100 nm. 
 
            
Figure 4.4: Increased magnification of 200 nm PEG-NLs in filtered PBS. The liposome is round in 






4.3 The characterisation of immunogold conjugated AB-NLs 
PEGylated liposomes were produced with the incorporation of gold-conjugated antibodies 
(AB-NLs) to produce loaded liposome samples for TEM analysis. Immunogold (10 nm) 
conjugated goat anti-fluorescein antibody was used for liposome incorporation. This antibody 
is a gold conjugate and can be visualised by TEM despite its small diameter. The vesicles 
therefore did not require negative PTA staining for visualisation. Consideration was given to 
the incorporation step for antibody loading. Liposomes of 200 nm in diameter were loaded 
with antibody at two different stages of production. Liposomes were additionally washed to 
remove non-bound excess antibody. Liposomes of 200 nm diameter were thought to be the 
best candidate to obtain the highest antibody encapsulation efficiency. 
 
4.3.1 AB-NLs (after lipid film rehydration) - 200 nm 
At first, the antibody was added to the preparation after rehydrating the lipids in filtered PBS. 
Immunogold conjugate (10 µL) was added to the 200 nm liposome sample (3 mM). As shown, 
the vesicles were regular in shape, but varied in size (Figure 4.5 and 4.6). The antibody 
appeared to be randomly distributed, with no evidence for selective incorporation into any 





             
Figure 4.5: First attempt at AB-NLs (200 nm) in filtered PBS The negative staining micrograph 
shows liposomes with gold-conjugated antibody added after lipid film rehydration in filtered PBS. 
The liposomes are round in shape and smaller than 200 nm in diameter. The antibody appears to 
be randomly distributed.  
 
              
Figure 4.6: First attempt at AB-NLs (200 nm) in filtered PBS. The negative staining micrograph 
shows liposomes with gold-conjugated antibody added after lipid film rehydration in filtered PBS. 
The liposome is round in shape and smaller than 200 nm in diameter. Antibodies appear randomly 




Figure 4.7 gives a graphical comparison between the number of antibody-conjugated gold 
particles found to be residing inside liposomes (40.05 ± 13.81 per µm2) and those in 
surrounding non-liposomal areas (11.74 ± 3.92 per µm2). There was no significant difference 




Figure 4.7: Gold-conjugated antibody found in liposome and non-liposomal areas, when added 
after rehydration. The graph shows gold particles/unit area (µm2) on the y-axis and antibody 
location (liposomal or non-liposomal area) on the x-axis. Bars show average ± SD (n=9) at a 3 mM 
































4.3.2 AB-NLs (before hydration, no wash) - 200 nm 
Due to the results obtained when antibody was added after the lipid rehydration step, an 
alternative method was conducted in order to increase the encapsulation efficiency of 
antibody into liposomes so that there is clear selective incorporation into the liposomes in 
comparison with the surrounding area. This involved the addition of antibodies to the lipid 
mixture before rehydration in filtered PBS. The theory is that incubation of the dry lipid film 
with antibody would allow more effective encapsulation when vesicles are subsequently 
formed upon rehydration (Figure 4.8). Therefore, 10 µL of immunogold conjugate was added 
to the lipid film, incubated for 3 mins, and vortexed extensively. Filtered PBS (1 mL) was added 
and the liposomes were otherwise produced as normal.  
 
 
Figure 4.8: Schematic showing the two methods of antibody encapsulation in liposomes. 
Antibodies were first added after the rehydration of the lipid film with filtered PBS (a). A second 
strategy applied the antibodies to the lipid film before rehydration, which was likely to improve the 
encapsulation efficiency (b). 
 
The 200 nm antibody loaded liposomes (before rehydration) were regular in shape but were 
often considerably larger than expected (Figure 4.9 and 4.10). Lipids appear as droplets rather 
than liposomes. The gold particles showed much better association with the lipid vesicles. 
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Figure 4.9: Alternative method for antibody loaded liposomes (200 nm) in filtered PBS. The 
negative staining micrograph shows antibodies added before the lipid film rehydration in filtered 
PBS. The liposomes are irregular in shape and structure with increased diameter than expected. 
Antibodies appear to be clustered at vesicles. 
 
         
Figure 4.10: Alternative method for antibody loaded liposomes (200 nm) in filtered PBS. The 
negative staining micrograph shows antibodies added after lipid film rehydration in filtered PBS. 
The liposomes are irregular in shape and structure with diameter close to 200 nm. Antibodies 





Figure 4.11 shows a graphical comparison between the numbers of gold-conjugated 
antibodies associated with liposomes and those in surrounding non-liposomal areas. The 
liposomal area gave a mean count of 103.84 ± 17.29 gold particles/µm2, whereas the non-
liposomal area gave a mean count of 2.07 ± 0.66/µm2, with this difference being statistically 
significant (p<0.0001). 
 
Figure 4.11: Antibody in liposome and non-liposomal areas (before rehydration, no wash). The 
graph shows gold particle location (liposomal or non-liposomal area) on the x-axis and antibody 
particles/unit area (µm2) on the y-axis. Bars show average ± SD (n=10) at a 3 mM (total lipid) 
liposome concentration. Results were statistically significant (p<0.0001). 
 
4.3.3 AB-NLs (before hydration, with wash) - 200 nm 
A washing step was developed in order to remove any excess antibody not incorporated into 
the lipid vesicles. Antibody loaded liposomes were prepared, by adding the antibody to the 
lipid film before rehydration. They were then centrifuged at 50K rpm [~ 257 xg max 
(RCFmax)] for 1 h at 4°C (70.1 Ti rotor) and resuspended in filtered PBS. The 200 nm liposomes 
loaded with antibody were irregular in shape and closer to 100 nm in diameter (Figure 4.12 
and 4.13). The lipids appeared to be more like ‘solid’ droplets than liposomes. The gold 
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particles were mainly associated with the lipid vesicles, with almost no gold-conjugated 
antibody present outside of them. 
 
 
Figure 4.12: AB-NLs (200 nm) in filtered PBS (added before hydration, with wash). The liposomes 
are irregular in shape with a diameter close to 100 nm. Lipids appear as droplets instead of 
liposomes. Antibodies are entirely clustered at the site of the lipid vesicles. 
 
 
Figure 4.13 AB-NLs (200 nm) in filtered PBS (added before hydration, with wash). The liposomes 
are irregular in shape, some of which have diameter close to 100 nm. Antibodies are entirely 






Figure 4.14 is a graphical comparison between antibodies residing in liposomes and those in 
surrounding non-liposomal areas. Liposomal area showed a mean count of  263.22 ± 66.14 




Figure 4.14: Antibody in liposome and non-liposomal areas  (before rehydration, with wash). The 
graph shows gold particles location (liposomal or non-liposomal area) on the x-axis and antibodies 
































4.4 The characterisation of RI-OR2-TAT and Alexa Fluor loaded liposomes 
Antibody loaded liposomes were produced with the incorporation of b-Actin Rabbit mAb 
(Alexa Fluor 594 Conjugate) for TEM analysis. Alexa Fluor cannot be detected on TEM, but the 
size and ultrastructure of the loaded liposomes can still be observed. Antibody incorporation 
was conducted by means of the most efficient protocol (before rehydration, with wash). 
Additional modification with amyloid-b peptide inhibitor RI-OR2-TAT-Cysteine ((Ac-
rGffvlkGrrrrqrrkkrGyc-NH2) was also performed. The size and ultrastructure of NL, AB-NL, RI-
OR2-TAT-NL and RI-OR2-TAT+AB-NL modified liposomes (3 mM total lipids) was examined by 
TEM. Produced vesicles required negative PTA staining for visualisation. It was clear that 200 
nm AB-NLs allowed incorporation of sufficient antibody, therefore liposomes of 100 nm in 
diameter were used for RI-OR2-TAT and Alexa Fluor loaded antibodies. This is because 100 nm 
liposomes are large enough to allow substantial antibody incorporation and small enough to 
allow passage across the BBB and uptake into cells. 
 
4.4.1 AB-NLs (Alexa Fluor) 
Alexa Fluor loaded liposomes were prepared for TEM, at 3 mM total lipid concentration. This 
followed the same protocol as refined by the immunogold conjugate experimentation, adding 
the antibody before the rehydration of the lipid film and then washing away excess antibody. 
Alexa Fluor would be undetectable by TEM, but the ultrastructure and size of the liposomes 
can be observed. 
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Figure 4.15: AB-NLs (100 nm) in filtered PBS (added before hydration, with wash). The liposomes 
are regular in shape and have diameter close to 100 nm. Ultrastructure and size is appropriate and 
few are clumped. 
 
          
Figure 4.16: AB-NLs (100 nm) in filtered PBS (added before hydration, with wash). The liposomes 
are regular in shape and have diameter close to 100 nm. Ultrastructure and size is appropriate and 





RI-OR2-TAT-NLs were prepared for TEM at 3mM (total lipid). RI-OR2-TAT is undetectable by 


















                  
Figure 4.17: RI-OR2-TAT-NLs (100 nm) in filtered PBS. The negative staining micrograph shows 100 
nm RI-OR2-TAT peptide inhibitor attached to liposomes. The liposomes are regular in shape and 
many have diameter close to 100 nm. Ultrastructure and size is appropriate, although many are 
clumped. 
                                
Figure 4.18: RI-OR2-TAT-NLs (100 nm) in filtered PBS - high magnification. The negative staining 
micrograph shows a higher magnification of Figure 4.43 micrograph, with 100 nm RI-OR2-TAT 
peptide inhibitor modified liposomes. Black arrows show unilamellar liposomes, red arrows show 





RI-OR2-TAT modified liposomes loaded with Alexa Fluor were prepared for TEM at 3mM (total 
lipid). This followed the same protocol as refined by the immunogold conjugate 
experimentation, adding the antibody before the rehydration of the lipid film and then 
washing away excess antibody. RI-OR2-TAT was then attached after liposome extrusion. Both 
RI-OR2-TAT and Alexa Fluor would be undetectable by TEM, but the ultrastructure and size of 
the liposomes can be observed. 
 
 
            
Figure 4.19: RI-OR2-TAT+AB-NLs (100 nm) in filtered PBS. The liposomes are regular in shape and 
many have diameter close to 100 nm. Red arrows show that some liposomes are multilamellar, 








CHAPTER FIVE – Wako Assay Results 
 
5.1 Wako assay (FUJIFILM Phospholipids C assay) refinement to determine liposome 
concentration 
The calculation of exact total lipid concentration (µg/mL) in liposomes can be problematic. 
The lipid concentration can be estimated based on the quantity of lipid or DSPE-PEG-MAL 
weighed out for production, but once the liposomes are extruded, some of that lipid will not 
be incorporated into liposomes, therefore reducing the total lipid concentration. Also, the lipid 
components will have combined together to form vesicles which are now difficult to assay. 
The FUJIFILM Phospholipids C assay (Wako assay) is an enzymatic method utilising choline 
oxidase in a reaction that is measured photometrically. The assay can measure SM 
concentration in solution, and was therefore used to determine the SM concentration in the 
liposomes made for this project. SM is present at 47.5 molar % in PEGylated liposomes, and 
so the concentration obtained from the Wako assay must be multiplied by ~2.1 to reach the 
actual total lipid concentration of the liposomes (100 molar %). It is apparent that in order for 
this assay to work effectively, the SM must be dissolved in a solvent. The liposomes must also 
be lysed in order for the sphingomyelin to be exposed to the enzymatic reaction. This section 
considers different solvents and preparation methods for the Wako assay in order to 








5.2 Standard curve for phospholipid solutions 
A standard lipid solution (3 mM) was provided as part of the LabAssayTM Phospholipid (Choline 
Oxidase-DAOS method) kit. The chromogenic substrate and enzyme exist as a powder that 
after reconstitution in substrate buffer (1:1), produce a photometric product. Absorbance was 
measured at 600 nm to produce a standard curve (Figure 5.1). Each test sample was analysed 
alongside a standard curve in order to obtain the corresponding phospholipid concentration. 
A standard curve was repeated for each experiment. 
 
 
Figure 5.1: Wako assay standard curve. The standard dilutions absorbance was measured to 
produce a standard curve. Curve has equation y=0.0887x + 0.01. R2 = 0.9998. This suggests the 



























5.3 Sphingomyelin in various solvents and conditions 
Before lysing and measuring the SM concentration in liposomes, free SM was dissolved in 
different solvents, under different conditions in order to evaluate which of these methods 
would allow SM concentration to be most accurately calculated. Conditions included 5 mins 
of heat block (50°C), sonication (50°C) or  no incubation, followed by 10 mins incubation at 
37°C.  SM was dissolved in each of the following solutions: PBS, Chloroform (Chl), Chl + 
Methanol (Chl/Me) (2:1), PBS + 0.1% Triton X-100 (Tr X), PBS + 2% Tr X and PBS + 2% Tr X in 
Me. SM has been shown to dissolve effectively in Chl, Me and in a mixture of both. Tr X is a 
detergent that can be used to lyse liposomes. Chl. and PBS as solvents alone showed 
significantly decreased lipid concentration, compared to other solvents. All other samples 
produced similar lipid concentrations, with any differences for the various solvent conditions 
being insignificant. 
 
Figure 5.2: Wako assay lipid concentration of SM in various solvents. The graph shows lipid 
concentration (mg/mL) on the y-axis and SM in various solvents and preparation methods on the 
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Table 5.1: One way ANOVA for Wako assay comparing SM in various solvents. Table shows the 
significance between no incubation, heat block (50° C) and sonication (50° C) groups comparing 





5.4 Sphingomyelin in various solvent volumes with Triton-X 
Results from SM in various solvents and conditions highlighted that the solvent itself, rather 
than the preparation method, was the most influential factor on the success of the assay. As 
a consequence, SM was then dissolved in different volumes of solvents for observation. 
Samples were produced in a ratio of solvent to Tr X in PBS, which included 50:50, 40:60, 30:70, 
20:80 and 10:90. This was conducted to determine whether the volume of solvent or Triton-X 
was influential on achieving the expected lipid concentration. Chloroform did not perform well 
as a solvent in the SM previously. Therefore, only PBS and methanol were used as solvents in 
a solution with 0.1% Tr X and 2% Tr X (Figure 5.3). This would determine which solvent is more 
effective and if an increased Tr X concentration is beneficial. It was shown that the ratio of 




Figure 5.3: Wako assay lipid concentration of SM in various solvent volumes with Tr X. The graph 
shows lipid concentration (mg/mL) on the y-axis and SM in various volume ratios of solvents and Tr 
X on the x-axis. Bars show average ± SD (n=3) at a SM concentration of 12 mg/mL. Significance 
























SM in various ratios of Triton-X




Table 5.2: One way ANOVA for Wako assay comparing SM in various solvent volumes with Tr X. 
Table shows the significance between various ratios of solvent solutions with Tr X (Figure 5.3). 
Groups include 0.1% Tr X in PBS, 2% Tr X in PBS, 0.1% Tr X in PBS+Me and 2% Tr X in PBS+Me 









5.5 Liposomes and SM in different solvents in 0.1% Triton-X 
Having characterised the Wako assay for SM, liposomes were now subjected to these same 
conditions to observe if the SM in liposomes can also dissolve and be measured effectively. 
Results shown in Figure 5.2 and 5.3 suggested that 0.1% Tr X was sufficient for SM to dissolve, 
and therefore was the only concentration of Tr X used. SM and liposomes in PBS and PBS + Me 
were prepared in 0.1% Tr X (3 mg/mL). SM showed lipid conc. for PBS and PBS + Me samples 
to be 2.85 and 2.60 (mg/mL) respectively, as expected. Liposome results showed lipid conc. 
for PBS and PBS+Me to be 0.40 and 1.98 (mg/mL) respectively. Lipid concentration was 
significantly increased in PBS+Me over PBS alone. 
 
 
Figure 5.4: Wako assay lipid concentration of SM and liposomes in various solvents and 0.1% Tr 






Figure 5.5: Wako assay lipid concentration of SM and liposomes in various solvents and 0.1% Tr 

















5.6 Liposomes in different solvents in 0.1% Triton-X 
Liposomal SM was most effectively dissolved in PBS + Me as shown in Figure 5.5, yet did not 
reflect the expected SM concentration in liposomes. Chl has been shown to enhance liposome 
lysis and SM dissolution. An assay was prepared with liposomes (3 mM total lipids) in PBS, 
PBS+Me and PBS+Me +Chl, in Tr X in order to determine if Chl is effective. Results showed lipid 
conc. of PBS, PBS+Me and PBS+Me+Chl to be 0.50, 0.78 and 0.87 (mg/mL) respectively (Figure 
5.6). The use of both PBS+Me and PBS+Me+Chl resulted in significantly increased lipid 
concentration compared with PBS. 
 
Figure 5.6: Wako assay lipid concentration of liposomes in various solvents and 0.1% Tr X. The 
graph shows lipid concentration (mg/mL) on the x-axis and liposomes in PBS, PBS + Me and PBS + 
Me + Chl, and 0.1% Tr X on the y-axis. Bars show average ± SD (n=3) at a liposome concentration 






CHAPTER SIX – Cell Penetration Results 
 
6.1 Cell penetration assay – Fluorescent microscopy 
Tau aggregation occurs intracellularly, therefore anti-tau therapeutics must be able to 
penetrate into neuronal cells in order to inhibit or prevent this aggregation. There is some 
evidence that Ab aggregation begins inside cells, suggesting that it may also be beneficial for 
Ab therapeutics to penetrate into cells. As a result, an important feature of antibody loaded 
liposomes includes their ability to penetrate into neuronal cells. In the following assay, 
fluorescent BODIPY liposomes (100 nm) with various modifications were prepared at different 
lipid concentrations (50 µM, 100 µM and 200 µM). Modifications included: PEG-NLs, AB-NLs, 
RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs. Prepared liposomes were incubated in standard 
mammalian cell culture conditions with SH-SY5Y neuroblastoma cells for 2 h and cell 
penetration was observed by confocal microscopy (LSM 510 – Laser Module – ZEISS). Different 
filters were used throughout the experimentation, including Dapi (blue), Bodipy (green), Alexa 
Fluor (Alexa) (red) and brightfield. These were used individually or in combination to portray 
results. 
 
6.2 BODIPY liposomes and control 
BODIPY-cholesterol is a fluorescent boron dipyrromethene difluoride linked to sterol carbon-
24 and was used to identify the location and abundance of liposomes by fluorescent 
microscopy. BODIPY PEG-NLs were compared with a control (prepared with normal 
cholesterol) to confirm that there was no background fluorescence present. Figure 6.1 shows 
images of fluorescent liposomes and this negative control. The DAPI and brightfield confirm 
the presence of cells, which was evident in both samples. Little or no green fluorescence was 
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observed in the negative control, as expected. In some cases, the cells produce a weak signal 
due to auto-fluorescent properties. 
 
 
Figure 6.1: Comparison between PEG-NLs with and without BODIPY (100 µM). Micrographs A-D 
show images of SH-SY5Y cells incubated with PEG-NLs (negative control) and E-H show images of 
SH-SY5Y cells incubated with BODIPY PEG-NLs (fluorescent liposomes). The columns represent the 
different filters. By comparing A-D to E-H, we can observe that both the fluorescent liposomes and 
negative control show cells on the brightfield that are stained by DAPI. The negative control did not 











6.3 PEGylated liposomes 
SH-SY5Y cells were incubated with BODIPY PEG-NLs at different lipid concentrations (0 µM, 50 
µM and 200 µM) to determine the impact of liposome concentration on cellular uptake, in 
absence of any additional modifications. Figure 6.2 shows that an increase in liposome 
concentration leads to a greater cellular uptake, as expected. 
 
 
Figure 6.2: SH-SY5Y cells with BODIPY PEG-NLs at different concentrations. A-C shows dapi + 
bodipy filter, D-F shows bodipy filter alone. A+D, B+E and C+F show liposome concentrations 0 µM, 
50 µM and 200 µM respectively. By comparing AD, BE and CF, we can observe that PEG-NLs are 
able to penetrate cells, and 200 µM  liposomes penetrate with greater efficiency than 50 µM. Scales 






6.4 Alexa Fluor loaded liposomes 
It is clear that liposomes can penetrate into SH-SY5Y neuroblastoma cells, as shown in the 
BODIPY PEG-NLs. The quantity of antibody that can be incorporated into liposomes and 
delivered into cells can now be determined, by incubating the SH-SY5Y cells with BODIPY AB-
NLs (using Alexa Fluor). Alexa Fluor is a fluorescent conjugated monoclonal antibody that 
detects b-Actin in cells, and can be visualised by fluorescent microscopy. BODIPY AB-NLs were 
prepared at different lipid concentrations (50 µM and 200 µM) in order to observe cellular 
uptake. Figure 6.3 shows the BODIPY filter for the alexa fluor liposomes. The SH-SY5Y cells 
with 200 µM BODIPY AB-NLs had more intense bodipy fluorescence than the 50 µM, as 
expected. Figure 6.4 shows the Alexa filter, which exhibits no cellular uptake of Alexa Fluor for 
the 50 µM BODIPY AB-NLs and limited uptake at 200 µM. 
 
Figure 6.3: Bodipy micrograph - SH-SY5Y cells with BODIPY AB-NLs at different concentrations. 
Columns show filters with bodipy and bodipy + dapi for comparison. A,B and C,D shows  liposome 
concentrations 50 µM and 200 µM respectively. By comparing A,B and C,D, we can observe that 
BODIPY AB-NLs are able to penetrate cells, and 200 µM  liposomes penetrate with greater efficiency 
than 50 µM. Scales bar = 20 µm. 
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Figure 6.4: Alexa micrograph - SH-SY5Y cells with BODIPY AB-NLs at different concentrations. 
Columns show filters with Alexa and Alexa + dapi for comparison. A,B and C,D shows liposome 
concentrations 50 µM and 200 µM respectively. By comparing A,B and C,D we can observed that 
limited antibody is present the cells. Scales bar = 20 µm. 
 
6.5  RI-OR2-TAT and RI-OR2-TAT+AB modified liposomes 
RI-OR2-TAT peptide was attached to liposomes, producing  to RI-OR2-TAT-NLs  and RI-OR2-
TAT+AB-NLs, to observe the impact on cellular uptake. RI-OR2-TAT is a CPP that has the ability 
to allow enhanced transport into cells. SH-SY5Y cells were incubated with these modified 
liposomes at different lipid concentrations (50 µM, 100 µM and 200 µM). Figure 6.5 and 6.6 
shows SH-SY5Y cells incubated with RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs respectively. The 
figures suggest that the SH-SY5Y cells have high affinity for liposomes with RI-OR2-TAT 
attached, shown by the bodipy micrographs. Alexa Fluor uptake is limited, but is increased at 




Figure 6.5: SH-SY5Y cells with RI-OR2-TAT-NLs at different concentrations. A-C, D-F, G-I, J-L show 
different filters of 50 µM, 100 µM and 200 µM liposome concentrations. A-F shows cells have high 
affinity for liposomes, which is increased at higher concentrations. G-L shows cells have limited 






Figure 6.6: SH-SY5Y cells with RI-OR2-TAT+AB-NLs at different concentrations. A-C, D-F, G-I, J-L 
show different filters of 50 µM, 100 µM and 200 µM liposome concentrations. A-F shows cells have 
high affinity for liposomes, which is increased at higher concentrations. G-L shows cells have limited 
fluorescence from Alexa Fluor at 50 µM liposomes, which is increased at higher concentrations. 






The micrographs obtained with SH-SY5Y cells incubated with RI-OR2-TAT-NLs and RI-OR2-
TAT+AB-NLs were combined for comparison (Figure 6.7). The purpose of this was to observe 
the intensity of the bodipy and Alexa under the respective filters. BODIPY is more intense in 
both liposome types as the concentration is increased, as expected. There is small background 








Figure 6.7: SH-SY5Y cells with RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs. A-F shows the bodipy 
filter for both liposome types, G-L shows the Alexa filter for both liposome types. A-F shows cells 
have high affinity for liposomes, which is increased at higher concentrations. J-L shows cells have a 
limited background on the Alexa filter. G-I suggests Alexa Fluor fluorescence is limited at 50 µM 







CHAPTER SEVEN – Discussion 
 
7.1 Background 
36 million people are affected by AD worldwide, and this number is set to rise to over 115 
million by 2050, as populations age (WHO, 2006). AD is a neurodegenerative disorder that 
severely affects the functioning of the brain, triggering widespread neuronal and synaptic loss, 
memory impairment, and cognitive and behavioural disturbances (Prince et al., 2016). The 
underlying cause of AD is accepted to be the progressive accumulation of extracellular senile 
plaques, containing Ab, and NFTs, consisting of PHFs composed of hyper-phosphorylated Tau 
protein (Murphy and LeVine, 2010). The drugs currently available for the treatment of AD 
(acetylcholinesterase inhibitors, and the NMDA antagonist memantine) do not target any of 
these underlying disease mechanisms (Hansen et al., 2008). and do not slow the long-term 
progression of the disorder. Liposomes are a biocompatible and highly flexible drug delivery 
system, with the potential for carrying many different types of bioactive molecules across the 
BBB. Their physiological composition facilitates numerous modifications, in comparison to 
other nano-carriers. These attractive properties of liposomes have provoked an interest in 
their development as a possible new and more effective therapy for AD than conventional 
small molecule drugs or biological agents. 
 
RI-OR2-TAT is a peptide inhibitor with the capacity to inhibit Ab aggregation. It contains a 
retro-inverso version of the TAT sequence, which substantially enhances transport across the 
BBB, a metabolic and transport barrier that prevents access to the brain of ~98% of 
neurotherapeutics. Amongst all CPPs, TAT is the best described with the greatest success. 
Despite the promising potential of RI-OR2-TAT, it only inhibits Ab aggregation at relatively high 
concentrations, limiting its potential (Taylor et al., 2010; Sherer et al., 2015). The peptide was 
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then attached to stealth liposomes, which improved the potency of RI-OR2-TAT. Yet, i.v. 
injection in TG2576 mice showed that most of the dose accumulates in peripheral tissues 
which will be subject to clearance (Gregori et al., 2017). These therapeutic entities known as 
PINPS could be improved by incorporation of alternative or additional modifications. The 
current study looks to see if antibodies can be delivered into cells using liposomes. This might 
be useful for highly functionalised multi-drug targeting systems in the future. Anti-Aβ and anti-
Tau antibodies were not used for experimentation. Instead, various other types of monoclonal 
antibodies were used as a test system. The future use of antibody loaded liposomes can be 
determined through analyzing the ultrastructure, stability and cell penetration efficacy. 
 
7.2 Antibody incorporation 
The liposome preparation and characterization methods used were, in the majority, derived 
or adapted from previous studies. Modifications of the Bangham method were used to try and 
incorporate antibodies into both plain liposomes and PINPs. This preparation method is 
relatively straight forward and is routinely used in our laboratory, but antibody incorporation 
into our liposomes has not been attempted previously. PEGylated liposomes firstly underwent 
hydration of the thin lipid film with PBS, followed by the addition of antibodies. Immunogold 
(10 nm) conjugated goat anti-fluorescein antibody was used as a test system to see if this could 
be incorporated into the liposomes. This approach showed that the antibodies were randomly 
dispersed between the liposomes and the surrounding areas, as observed by TEM (Figure 4.5 
and 4.6). The encapsulation efficacy was poor and required improvement if it were to be useful 
as a system to deliver antibodies.  
 
It was hypothesised that the addition of antibodies to the lipid film before rehydration of PBS 
would lead to them interacting with the film so that sequential rehydration would ensure a 
good encapsulation efficacy (Figure 4.8). This was the case, the results before rehydration 
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showed that antibodies were situated around or in liposomes (Figure 4.9 and 4.10). Analysis 
of this data showed antibodies per liposomal area (µm2) were significantly increased 
compared to antibodies per non-liposomal area (Figure 4.11), suggesting that adding 
antibodies before lipid film rehydration provided more effective encapsulation than adding 
them after rehydration. A drawback from TEM is the difficulty in determining whether the 
antibodies are encapsulated inside liposomes, integrated into the lipid bilayers, or resting on 
the outside of the vesicles. However, if they were solely in the membrane, they would most 
likely be grouped in the bilayers, so it is highly likely that they are inside the liposomes. 
 
In order to improve the reliability of the TEM micrographs, a washing step was introduced to 
remove any free (non-bound) bound antibodies from the solution containing the liposomes. 
A series of steps involving centrifugation, discarding of supernatant, and resuspension of 
liposomes in PBS, was repeated three times and TEM micrographs were then produced (Figure 
4.12 and 4.13). Results showed that all antibodies across 8 micrographs were situated within 
(or at least closely associated with) liposomal areas and none resided outside of the liposomes 
(Figure 4.14). There was no apparent clustering on liposomal membranes. Instead the 
antibodies were dispersed evenly within liposomes, suggesting that the bulk of the antibody 
is contained within the liposome core, rather than being contained within or attached to the 
lipid bilayers. Based on these images, it is clear that these liposomes have the potential to trap 
and deliver the antibodies to a therapeutic target. 
 
7.3 DLS investigation 
Characterisation of liposomes was conducted by DLS. Colloidal gold standards were first 
measured at optimum dilutions in order to calibrate and validate the technique for the 
liposome samples. The gold nanoparticles at the dilutions tested were expected to give peaks 
at their respective vesicle size, with low PDI and SD. Results gave the expected mean vesicle 
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diameter for each sized sample (Figure 3.1), but the SD was high, particularly at higher gold 
nanoparticle sizes. This is likely to be due to clumping in solution, producing varied particle 
sizes. This is unusual as DLS, when conducted at appropriate dilutions for each nanoparticle 
size, should give tight and accurate measurements. It is possible that the colloidal gold samples 
were aged, or unusually clumped in solution. Overall, the PDI remained stable and the mean 
peak values were as expected, so it was decided that the system was reliable enough for 
further experimentation. Additionally, the experimental liposome samples have a PEGylated 
lipid incorporated into their membranes, which should reduce attractive forces (van der 
Waals) between them, and increase repulsive forces (Kenworthy et al., 1995a; Kenworthy et 
al., 1995b), therefore reducing any clumping observed. 
 
Following the system calibration, PEG-NLs of three distinct sizes (200 nm, 100 nm and 50 nm) 
were analysed by DLS at optimal dilutions (shown in Figure 3.3 and 3.4). Again it was expected 
that the DLS results would accurately reflect the anticipated diameters of the samples. The 
incorporation of the PEGylated lipid should result in an increased vesicle diameter compared 
with plain liposomes. Previous studies with PEG-DSPE at 7±2 molar % have suggested that a 
size increase of no more than 1.5 nm would be expected, yet an increase of 15 ± 5 nm was 
actually observed (Garbuzenko et al., 2005). Consequently, a similar increase in the current 
study is a possibility. The 200 nm liposomes gave a mean size of 213.50 ± 9.30 nm, as expected. 
Yet, their wide size distribution makes them undesirable for antibody encapsulation. Also, 
liposomes of 100 nm and smaller are considered to be more suitable for BBB transportation, 
and so 200 nm liposomes are likely to have limited uptake and delivery.  The 50 nm liposomes 
gave a mean size of 49.51 ± 0.49 nm, however, Figure 3.4 shows that a second peak at 220.70 
nm was observed. This peak suggests the liposomes are aggregating, even at a high dilution 
factor (1:500 dilution) and so 50 nm liposomes are unlikely to be suitable for AD therapy, as 
aggregated 50 nm liposomes will have limited mobility, have reduced BBB uptake and be 
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susceptible for immune system degradation. Additionally, a small diameter will limit the 
antibody incorporation efficiency, reducing its therapeutic potential. The 100 nm liposomes 
had a mean diameter of 180.30 ± 5.16 nm, much larger than anticipated. They were more 
narrowly distributed than 200 nm or 50 nm liposome samples and remain the most suitable 
vesicle size for antibody incorporation and potential brain delivery based on DLS results. The 
increased diameter could be due to vesicles clumping together, or abnormally shaped vesicle 
formation. 
 
AB-NLs were then analysed by DLS in order to evaluate the impact the antibody has on the 
size and stability of the vesicles. Since 50 nm vesicles are considered to be the least suitable 
for antibody incorporation and delivery, only 100 nm and 200 nm liposomes were produced 
for this purpose. There is limited data on AB-NLs, and so the expected results are not clear 
from the literature. It is thought, however, that 100 nm liposomes maintain the most stable 
size and distribution with antibody incorporation, a result shown in the PEG-NL results. It is 
possible that antibody incorporation could distort the vesicles, causing an increase in size or 
vesicle aggregation. Results showed that 200 nm AB-NLs had mean size of 196.7 ± 9.51 nm, 
and showed no significant difference to the PEG-NLs which had a diameter of 213.5 ± 9.30 nm 
(Figure 3.5). They also had greater intensity and lower PDI, suggesting that overall, they are 
more stable (Figure 3.6). The 100 nm AB-NLs were 213.5 ± 41.33 nm, and showed no significant 
difference to the PEG-NLs with a diameter of 180.3 ± 5.16 nm (Figure 3.7). However, the SD is 
increased, which could be as a result of the antibody incorporation. They had similar intensity 
but increased PDI, and some AB-NLs were as large as 250 nm in diameter (Figure 3.8). It is 
possible that antibody incorporation may have an impact on structure or cause liposomes to 
aggregate.  Assuming the structure of AB-NLs is normal (determined by TEM) rather than 
forming large irregular vesicles, this is unlikely to be problematic for experimentation. The 200 
nm liposomes would most likely be degraded quickly by the immune system, and are too large 
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for efficient BBB transportation. Based on this and TEM results, it was decided to use 100 nm 
liposomes for additional experimentation. 
 
Subsequent studies involved the analysis of RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs by DLS 
to assess the impact of attaching the peptide inhibitor to PEG-NLs and AB-NLs. Previous DLS 
studies have shown that RI-OR2-TAT-NLs are stable (Sherer et al., 2015), and so it is expected 
that RI-OR2-TAT-NLs will be stable in size and PDI . RI-OR2-TAT+AB-NLs have not been studied 
previously, and the expected outcome was somewhat unknown. Yet, unexpectedly, RI-OR2-
TAT-NLs had significantly increased diameter than PEG-NLs (Figure 3.9), and it is likely that the 
attachment of RI-OR2-TAT caused the vesicles to clump. RI-OR2-TAT+AB-NLs had a 
significantly increased diameter than PEG-NLs and AB-NLs. It appears that the attachment of 
RI-OR2-TAT, rather than the incorporation of antibodies, is causing the diameter to increase. 
Both of the RI-OR2-TAT modified liposomes are roughly twice the expected size. It is possible 
that the liposomes are aggregated in pairs, due to the process of RI-OR2-TAT attachment. This 
would have to be confirmed by further TEM studies. 
 
7.4 Wako Assay investigation 
The purpose of this investigation was to characterise the conditions required for the SM 
content of liposomes to be measured accurately, using the Wako Assay. After characterization, 
the assay could then be used in the future to accurately determine how much of the lipid 
weighed out is integrated into liposomes and how much is lost. A standard curve, using Wako 
assay standard solution, was initially produced in order to assess the accuracy of the Wako 
Assay kit (Figure 5.1). The phospholipid concentration (mg/mL) measured gave a good line of 
best fit with a high R2 value (0.9998), which suggests that the assay kit is reliable.  
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Before experimentation, it was expected that strong organic solvents such as Me and Chl 
would be the most successful for measuring SM content as they have been shown previously 
to dissolve this lipid. As a detergent, Tr X lyses liposomes, and is therefore thought to be 
beneficial for the assay to detect SM in solution. Yet, the most effective combination of 
solvents and incubation conditions is likely to change for different SM concentrations and in 
different liposomal vesicles. As a result, SM was firstly assayed alone (non-liposome) in a 
variety solvents and incubation conditions to determine which of them can most effectively 
measure SM concentration. The assay could then be further characterised to measure SM 
concentration in liposomes. Results showed that, other than Chl alone, all combinations of 
solvents and their various incubation conditions gave increased lipid concentration compared 
to SM (3 mg/mL) dissolved in PBS alone (Figure 5.2). The Chl result was unexpectedly poor, 
and suggests that Chl is only effective when used in combination with Me. SM dissolved in PBS 
and Tr X (with no additional solvent) produced similar results to SM dissolved in Chl/Me, and 
2% Tr X was not significantly increased compared with 0.1% Tr X. It would seem that 0.1% Tr 
X is sufficient to dissolve the 3mM SM in solution and there is no benefit of using an increased 
Tr X concentration.   
 
Since both of these approaches have shown success, it would be worthwhile to repeat the 
assay with both Tr X and solvents like Me to see if the impact is additive or synergistic on 
yielding the expected SM concentration. Since Chl was somewhat poor in the previous study, 
it was not included in this experiment. Also, different Tr X concentrations had no significant 
impact on SM yield. The study was instead conducted with various ratios of Tr X in order to 
determine if the volume of Tr X had an effect on the SM yield (12 mg/mL). It is difficult to know 
what to expect from this experiment. If the current ratio of lipid to solvent/Tr X (50:50) is 
sufficient, then alteration will likely have little effect. Whereas if an increased SM yield is 
observed, then the solvent/Tr X volume would have previously been a limiting factor. Results 
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showed that the ratio had no significant impact on lipid concentration; it is therefore assumed 
that the concentration of solvent/Tr X is not limiting the ability for the assay to detect SM.  
 
Apart from a few unexpected results (e.g. 40:60 ratio of 2% Tr X in Me), the concentration of 
lipid yielded from the assay ranges from approximately 75-90% of the total SM that was added 
to the solution. This is sufficient to assume that the majority of lipid is being detected by the 
assay under optimised conditions and the assay can now be used to detect SM in liposome 
samples. 
 
Liposomes must be lysed in order to effectively measure their lipid concentration. Tr X is 
known to lyse liposomes and is almost certainly required for the assay to be successful. The 
solvent/Tr X conditions optimised for previous experiments on SM will be used for liposomes 
in order to observe if these conditions are effective. It would be expected that the use of a 
strong solvent such as Me and Chl would be more effective than PBS alone. While SM samples 
may effectively dissolve in PBS alone, liposomes often require additional solvents in order to 
dissolve all the lipid formed in bilayers. As expected, Figure 5.4 and 5.5 shows that the lipid 
concentration yielded from liposomes is significantly increased in PBS + Me compared with 
PBS alone. This is not the case in the SM sample, where both PBS and PBS + Me both show 
concentrations close to 3 mg/mL. This confirms that a solvent is important to dissolve 
liposomes, yet not important for dissolving free SM in solution. For this sample, it is likely that 
the processes of heating and sonication as well as Tr X are sufficient to dissolve the majority 
of the lipid. Figure 5.5 confirms that liposomes in PBS + Me still yield a significantly lower lipid 
concentration than SM in the same conditions. This suggests that there could be SM in 
liposomes still not dissolved in PBS + Me. Since a ratio of Me to Chl (1:1) has proven successful 
in previous experimentation as well as in above results, this is a good strategy to improve 
accuracy of measuring the lipid concentration of liposomes. 
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Figure 5.6 shows a comparison between liposomes treated in PBS, PBS + Me and PBS + Me + 
Chl (1:1). The greatest lipid concentration observed was those treated with PBS + Me + Chl 
(0.87 mg/mL), which was significantly different from PBS (0.5 mg/mL). Yet, there was no 
significance with PBS + Me, regardless of the higher lipid concentration. The total lipid 
concentration for this study was expected to be ~3 mM, which was calculated based on the 
volumes of lipid weighed out during liposome preparation. When converted to millimolar, the 
0.87 mg/mL of SM observed in this study is the equivalent of 1.34 mM. The SM content in 
these liposomes is only ~50 molar % of the total lipid content, so 1.34 mM can be doubled, 
producing 2.67 mM, to produce an estimate of total lipid in liposomes. Based on the total lipid 
weighed into solution, the total lipid conc. was expected to be ~3 mM, which suggests that 
there is a 10.9% loss of lipid in liposomes compared with the original lipid weighed. Taking into 
account that there will be loss of lipid dehydration and rehydration and also in the final 
solution where some lipid won’t have formed liposomes, the concentration observed in the 
assay has detected the large majority of lipid in solution and any lipid loss is likely to be due to 
these factors involving liposome preparation.  
 
This Wako Assay method and the refined treatment conditions can now be used in the future 
to determine the actual concentration of lipid in solution and therefore effectively estimate 
the overall lipid content of liposomes. 
 
7.5 TEM investigation 
TEM not only compliments DLS by providing additional information on the size, shape and 
ultrastructure of nanoliposomes, but it was essential in order to observe antibody 
encapsulation. Many characteristics that were not revealed by DLS were shown by TEM. For 
example, key observations included the impact that antibody encapsulated has on the 
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liposome structure. The ability to visualise liposomes by TEM also allowed quantitative data 
to be produced and analysed to refine encapsulation techniques to improve efficiency. Four 
types of nanoliposome (PEG-NL, AB-NL, RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs) of different 
sizes (50 nm, 100 nm and 200 nm) were imaged and analysed. 
 
Other than size and general structure, one key structural characteristic revealed by TEM is the 
lamellarity of all liposome types. The freeze thawing and sonication preparation methods used 
here should produce unilamellar vesicles rather than multilamellar vesicles (Traïkia et al., 
2000). In addition to observing if the preparation methods used here produce unilamellar PEG-
NLs, it was also worthwhile to investigate if any other liposome types, with attached peptide 
inhibitor or incorporated antibody, have altered lamellarity. Figures 4.1-4 show TEM 
micrographs of various sizes of PEG-NLs. Depending on the particular micrograph, some show 
clear unilamellar vesicles, e.g. Figure 4.1 and 4.3, and all micrographs produced liposomes with 
vesicles that varied slightly in size, but were in the large majority, stable in size and structure. 
Based on this, it is clear that the current preparation method produces desired vesicles, most 
of which are unilamellar.  
 
The study involving the incorporation of gold-conjugated antibodies did not require negative 
staining, and so the resulting micrographs (Figure 4.5-6 and 4.9-10) are not ideal for 
determining lamellarity. However, results show the characterization of RI-OR2-TAT and AB 
modified liposomes, which shows unilamellarity in AB-NLs (Figure 4.16), RI-OR2-TAT-NLs 
(Figure 4.18) and RI-OR2-TAT+AB-NLs (Figure 4.19) in some high magnification micrographs. 
RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs also show some liposomes that are multilamellar. It 
is possible that the modification has caused a change in the ultrastructure and so some 
multilamellar vesicles are formed. Yet, the majority remain unilamellar and those that are 
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multilamellar have only 2-3 layers. Overall, it would seem that the lamellarity is fairly stable 
for all the liposome types. 
 
7.6 Cell penetration investigation 
An important characteristic of AB-NLs is their ability to penetrate cells. In order to do this, 100 
nm bodipy liposomes with modifications: NLs, AB-NLs, RI-OR2-TAT-NLs and RI-OR2-TAT+AB-
NLs were produced, and tested at various concentrations on neuroblastoma SH-SY5Y cells and 
measured for cellular uptake. Alexa Fluor antibodies were used for fluorescence observation 
and were observed under the red filter (referred as Alexa). BODIPY chl also used and was 
observed under the green filter (referred as Bodipy). The Alexa filter was likely to give insight 
into situation and quantity of antibodies in cells, whereas the BODIPY chl will track what 
happens to the liposome once entering the cells. The two filters together were thought to give 
insight into whether it is possible to transport antibodies into cells using liposomes, and also 
what happens to them once inside (Holtta-Vuori et al., 2008). 
 
An initial study showed the effectiveness of this experiment (Figure 6.1), showing that 
liposomes with and without bodipy cholesterol give clear differences under the Bodipy filter. 
PEG-NLs of different concentrations showed a clear gradient in terms of their intensity under 
the Bodipy filter, suggesting that higher concentrations of simple PEG-NLs are more likely to 
penetrate SH-SY5Y cells. This was an observation that was also shown in AB-NLs (Figure 6.3), 
whereby an increase in liposome concentration appeared to increase cellular uptake. 
However, the Alexa fluorescence was unexpectedly poor, and there was only a very slight 
visual increase in fluorescence in the 200 µM compared with the 50 µM. The microscope was 
also set at maximum sensitively to detect the slightest fluorescent signal. It is likely that the 
amount of Alexa Fluor incorporated in the AB-NLs is insufficient to produce a greater signal, 
certainly in these liposomes that do not have RI-OR2-TAT attachment. 
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 As previously discussed, RI-OR2-TAT is a modified CPP that is known to enhance cellular 
uptake. RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs of various concentrations were produced to 
observe the impact RI-OR2-TAT has on cellular uptake in terms of the BODIPY and Alexa Fluor 
fluorescent markers that are observed. Figures 6.5 and 6.6 show that the BODIPY intensity is 
increased as the concentration increased, as expected. However, the overall intensity is far 
greater than the NL and AB-NLs, suggesting that the addition of RI-OR2-TAT has successfully 
increased the cellular uptake, without killing the cells. Figure 6.7 shows a comparison between 
RI-OR2-TAT-NLs and RI-OR2-TAT+AB-NLs. Alexa Fluor is only expected to be seen in the RI-
OR2-TAT+AB-NLs, however there appears to be red fluorescence also observed in RI-OR2-TAT-
NLs. Whilst this is unexpected, there are a few observations that can be used for evaluation. 
Firstly, the intensity in the RI-OR2-TAT+AB-NLs increased as the concentration increased, 
whilst in the RI-OR2-TAT-NLs, there remained a consistent intensity throughout all 
concentrations. This suggests that the fluorescence observed in the later, is background 
fluorescence from the liposomes, or the bodipy cholesterol, which can be backed up by the 
fact the spots of fluorescence on the red filter match up with that of the green, something not 
observed on the RI-OR2-TAT+AB-NLs. Overall, there is evidence to suggest that RI-OR2-
TAT+AB-NLs do transport antibodies into cells with greater success than AB-NLs alone. 
However, the quantity of antibody reaching the cells is likely still to be low. 
 
7.7 Future studies 
The production of these types of liposome carriers for brain delivery is still in its early stages 
of development. As a result, there are many types of studies that should be performed in order 
for this system to improve. A variety of different lipids should be trialled in all of the liposome 
types to observe the impact on liposome stability, which can be confirmed by DLS and TEM. 
Characteristics such as their shape, size, lamellarity and interaction with other molecules will 
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differ depending on the lipid composition of liposomes, and this is something that should be 
measured for vesicle optimisation.  
 
The key study that can be improved is the cell penetration investigation. The current study 
was informative, showed that antibodies can be delivered into neuronal cells, which was 
enhanced by the attachment of TAT. However, the uptake of the antibody was likely to be 
poor. There can be continuous re-evaluation of the antibody incorporation method in order 
to increase the incorporation efficiency, which will in theory allow the uptake of more 
antibodies into cells. The antibodies used for the current study were solely used to show that 
they could be transported into cells, and were not specific towards any AD pathologies. 
Additional studies could incorporate anti-Tau or anti-Ab antibodies into liposomes, and 
transport them into a cell line expressing Tau or Ab respectively. This would not only 
demonstrate the uptake efficiency but also the potential for using anti-Tau or anti-Ab 
antibodies therapeutically. A final study could also utilise a BBB model, by producing various 
types of liposomes and observing their ability to penetrate the BBB, which prevents 98% of 
potential neurotherapeutics from entering the brain. This will particularly highlight the 
effectiveness of CPPs such as TAT, and if their attachment can enhance the BBB penetrate. 
 
Overall, if studies can show that produced AB-NLs are stable and safe, can penetrate the BBB 
with the aid of various attachments and can be delivered into cells expressing AD pathologies 
and have a positive impact on these cells, then this system will have great potential to progress 
to clinical trials and therapeutic use. 
 
7.8 Conclusion 
Compared with plain liposomes, antibody loaded liposomes often had a tendency to clump. 
Other than this, there was no great impact size or ultrastructure of the vesicles and antibodies 
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have been shown to be effectively incorporated. However, the incorporation efficiency is likely 
to have been poor, and development of current antibody incorporation techniques is essential 
for improved uptake. Modified antibody loaded liposomes were also successfully delivered 
into SH-SY5Y cells, enhanced by the attachment of TAT. Fluorescence showed that antibody 
was also delivered into the cells by liposomes. This demonstrates the potential of antibody 
loaded liposomes for the treatment of AD. Extensive research is still required to improve and 
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Abstract: Alzheimer’s disease (AD) will affect around 115 million people worldwide by the year 
2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and 
tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs 
for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this 
disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive 
decline. However, there has been a spectacular failure rate in clinical trials of conventional small 
molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising 
drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, 
highly flexible, and have the potential to carry many different types of therapeutic molecules 
across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood 
circulation time and can be directed against individual or multiple pathological targets. Modi-
fications so far have included the use of brain-penetrating peptides, together with Aβ-targeting 
ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ 
aggregation. Combining several modifications together into multifunctional liposomes is cur-
rently a research area of great interest. This review focuses on recent liposomal approaches to 
AD therapy, including mechanisms involved in facilitating their passage across the BBB, and 
the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation.
Keywords: amyloid, blood–brain barrier, cell-penetrating peptides, neurofibrillary tangles, 
senile plaques, tau
Introduction
Alzheimer’s disease (AD) affects 36 million people worldwide, and this number is set 
to rise to over 115 million by 2050, as populations age.1 AD is a neurodegenerative dis-
order that severely affects the functioning of the brain, triggering widespread neuronal 
and synaptic loss, memory impairment, and cognitive and behavioral disturbances.2 
A major hypothesis regarding the underlying cause of AD is that the progressive accu-
mulation of protein aggregates in the brain leads to neurodegeneration and dementia3 
(see Karran and de Strooper4 for a critical review). These protein aggregates include 
extracellular senile plaques, containing the β-amyloid (Aβ) peptide, and neurofibrillary 
tangles (NFTs), consisting of intra-neuronal paired helical filaments (PHFs) composed 
of hyper-phosphorylated tau protein.5 Aβ spontaneously and progressively aggregates 
to form oligomers and amyloid fibrils, with oligomers being a strong candidate for 
inducing synaptic damage and memory deficits in AD.6 However, AD is likely to be a 
multifactorial disorder, with many mechanisms, including NFT formation, contribut-
ing to neuronal cell damage.
It is well established that Aβ and tau underlie the neuropathology of AD, but 
many aspects of the neuropathogenesis of this disease remain unanswered. There is 
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good evidence that aggregation and accumulation of these 
molecules induce membrane damage and oxidative damage 
through an increase in free radical production and promotion 
of pro-inflammatory processes.7–9 NFT formation is also likely 
to interfere with axonal transport systems. The drugs currently 
available for the treatment of AD (acetylcholinesterase inhibi-
tors [AChEIs] and the NMDA antagonist memantine) do not 
target any of these underlying disease mechanisms10 and do 
not slow down the long-term progression of the disorder. 
Instead, they provide only temporarily improved cognition by 
counterbalancing neurotransmitter disturbances, in addition 
to having many limitations and side effects.11 It is therefore 
essential to develop alternative therapies, with minimal 
adverse side effects, which aim to prevent, slow or reverse 
the neurodegeneration responsible for AD. Unfortunately, 
clinical trials on !200 drugs, with different molecular targets, 
have so far failed to find a therapeutic approach that arrests 
or reverses cognitive decline in patients with AD.12–14
Any effective treatment for AD would most likely require 
the therapeutic agent concerned to be transported across the 
blood–brain barrier (BBB),15 which prevents access to the 
brain of around 98% of potential neuropharmaceuticals.16 
Liposomes are a biocompatible and highly flexible drug 
delivery system, with the potential for carrying many dif-
ferent types of bioactive molecules across the BBB. The 
therapeutic potential of liposomes was recognized shortly 
after their development in 1961, but only recently they 
have been considered as a suitable vehicle for the delivery 
of drugs that act on the central nervous system (CNS).17,18 
Their physiological composition facilitates numerous modi-
fications, in comparison with other nano-carriers. Simple 
“non-targeted” liposomes can carry a drug cargo into the 
brain (eg, via the olfactory route, see “Intranasal delivery” 
section), but modified “targeted” liposomes are required for 
effective delivery across the BBB and can also be designed 
to interact with specific molecular targets relevant to the 
treatment or prevention of AD. Liposomes can incorporate 
hydrophilic or lipophilic/hydrophobic therapeutic agents, 
where hydrophilic drugs are entrapped in the aqueous core, 
and lipophilic compounds are contained in the hydrophobic 
region of the lipid bilayer.19 Moreover, various types of 
therapeutic agent can be attached to the surface of the lipo-
somes. These various configurations can be combined to give 
a targeted multi-drug delivery system, which is particularly 
relevant for the treatment of any multifactorial disease. These 
attractive properties of liposomes have provoked an interest 
in their development as a possible new and effective therapy 
for AD. This narrative review presents our own perspective 
on recent and promising liposome approaches to AD therapy, 
including mechanisms involved in facilitating their passage 
across the BBB, and the evaluation of new therapeutic agents 
for blocking Aβ and/or tau aggregation.
The BBB
The BBB is a metabolic and transport barrier that protects 
the brain from harmful stimuli. It comprises brain capillary 
endothelial cells that are attached to each other through tight 
junctions, resulting in restricted paracellular transport.20,21 
Degrading enzymes are also present at the BBB, which 
can destroy molecules during their attempted passage into 
the brain.22 However, specific mechanisms are in place for 
the BBB transport of molecules that are essential for brain 
function,23 and these can be exploited for therapeutic drug 
delivery.
early strategies for BBB transportation
Passive diffusion permits the passage of some small lipo-
philic compounds across the BBB, such as certain amino 
acids, nucleosides, and small peptides. An early strategy 
utilized this simple mechanism by developing small lipo-
philic drugs that might pass through the endothelial cells. 
However, this excluded the vast majority of potential thera-
peutic molecules. A second approach was to develop small 
water-soluble drugs, in order to facilitate BBB transport via 
the paracellular hydrophilic diffusion pathway. However, 
most of these potential molecules could not penetrate past 
the tight endothelial cell junctions.24
Alternatives
Intracerebral or intracerebroventricular injection of drugs 
provides a strategy that avoids the BBB, but these procedures 
are highly invasive, and so are not widely used. Drugs admin-
istered by any peripheral route (eg, orally or by intravenous 
injection) will encounter the BBB.25 Alternative methods, 
such as bypassing the BBB by delivery through the olfactory 
region (eg, as a nasal spray) have some potential.26–28 Another 
strategy looks to utilize existing active BBB transport mecha-
nisms, namely carrier-mediated transcytosis (also known 
as transporter-mediated transcytosis), receptor-mediated 




Several different types of nanoparticles (eg, solid lipid, mag-
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Liposome delivery for Alzheimer’s disease
Table 1 Transport mechanisms for BBB transit and brain delivery
Transport mechanism Explanation Examples
Carrier-mediated  
transcytosis
Some essential materials required in the brain have specific  
transporters for active uptake across the BBB. Drugs can  





Receptors on the BBB endothelium can bind specifically  
with corresponding ligands and trigger internalization. Drugs  





Cell-mediated endocytosis endocytosis into endothelial cells can deliver drugs across the  
BBB. This mechanism is almost unique to the action of CPPs  
which exhibit various features to trigger transportation, and  




Adsorptive transcytosis Adsorptive-mediated targeting utilizes a modified, positively  
charged biological macromolecule for interaction with the  
negatively charged BBB, based on electrostatic attraction
Cationized bovine serum albumin109
Cationized immunoglobulins/monoclonal 
antibodies105
Abbreviations: BBB, blood–brain barrier; CPPs, cell-penetrating peptides; TAT, transactivator of transcription of human immunodeficiency virus.
as possible vectors for AD therapy. A popular strategy is 
to aim for optimum brain selectivity by targeting receptors 
or transporters that are highly expressed at the BBB, and 
improving stability, for example, by using non-natural amino 
acids in the case of peptide drugs, so that they are resistant to 
proteolysis.30 A second route considers intranasal administra-
tion of the active compounds, without any BBB interruption. 
Recent studies have begun to focus on liposomes as a possible 
carrier of drugs for the treatment of AD.31–33
BBB transport
Possible mechanisms for the transport of liposomes across 
the BBB have been highly debated.25 An initial theory was 
that the phospholipid bilayer of the liposomes on its own 
might facilitate transportation across various biological 
membranes, including the BBB, but this simple mechanism 
proved to be ineffective. Modifications proposed for enhanc-
ing the transport of liposome carriers across the BBB utilize 
the existing active transport mechanisms, involving absorp-
tive, carrier- or receptor-mediated transcytosis.34 Absorptive 
methods take advantage of the BBB’s negative charge. Cat-
ionic liposomal drug vehicles have been developed that can 
trigger cell internalization through electrostatic interactions. 
However, the nonspecific uptake of the cationic liposomes 
by peripheral tissues and their binding to serum proteins has 
meant that a toxic dose would often be required to reach 
therapeutic efficacy,35 thus limiting therapeutic potential. 
Carrier-mediated transcytosis utilizes nutrients capable of 
passing across the BBB, such as glucose and glutathione 
(GSH), that can be attached to the surface of liposomes 
and facilitate translocation.19 Ultimately, receptor-mediated 
transcytosis has great potential for success, since there are 
possibilities to target one or more of the many different recep-
tors at the BBB by using their respective ligands. Yet there 
is still substantial interest in direct penetration of the BBB 
membrane, which has been achieved largely through the use 
of cell-penetrating peptides (CPPs) (Figure 1).
Intranasal delivery
A second route involves the intranasal administration of 
liposomes. This strategy avoids the BBB by offering direct 
nose-to-brain absorption through the olfactory and trigeminal 
nerves. Liposomal encapsulation of compounds can result in 
improved penetration via this route, by protecting them from 
degradation and facilitating their transport across the mucosal 
barrier. A recent study has demonstrated effective administra-
tion of a liposome-encapsulated “β-breaker” peptide, known 
as H102, using this strategy.27 Results showed satisfactory 
drug concentrations in the brain, with limited toxicity. Thus, 




Liposome size, as well as lipid composition, affects their 
circulation in the bloodstream and uptake into the brain.36,37 
Brain delivery requires liposomes to be roughly nano- or 
microsized and consists of one or more lipid bilayers sur-
rounding an aqueous core. Only certain sizes will allow pas-
sage across the BBB for neurotherapy (such as in AD) and so 
small vesicles (100 nm and less) are often preferred. There 
are studies, however, that have shown that liposomes from 
100 to 140 nm have certain advantages, such as a longer half-
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Large nano-liposomes (250 nm in diameter) are cleared twice 
as fast as 100 nm liposomes.38 Yet, liposomes 100 nm and 
smaller have more limited storage capacity, leading to poor 
encapsulation efficiency.39 A consideration of size should be 
made based on factors such as their therapeutic application, 
encapsulation efficiency, and stability.
Lipid composition
Phospholipids commonly used in liposomes include synthetic 
lipids such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
and ethyl-phosphatidylcholine, or natural lipids such as 
phosphatidylcholine (PC), sphingomyelin (SP), and leci-
thin (LC). Natural lipids are at risk of contamination from 
viruses, prions, or toxins, especially if they are isolated 
from a mammalian source, for example, bovine brain. They 
are, however, cheaper in large-scale production, use fewer 
solvents and other chemicals in their extraction, and are more 
readily accepted by regulatory authorities, especially when 
derived from a non-animal (eg, plant) source. Cholesterol is 
often added to liposomes during assembly, which not only 
maintains the stability of membranes in vivo and in vitro 
but also reduces permeability and alters the structure and 
function of the vesicles.40
Aβ has been shown to insert preferentially into any 
anionic phospholipids incorporated into liposomes, which 
could have a protective effect, by removing toxic Aβ.41,42 The 
majority of treatments aimed at AD have used PEGylated 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG 
2000 (DSPE) to improve circulation time (see “Stealth lipo-
somes” section), although wheat germ agglutinin, chitosan, 
silk fibroin, and polyvinyl alcohol have also been used to 
achieve similar “stealth” properties.
Figure 1 Promising liposomal BBB transport mechanisms.
Notes: Receptor-mediated transcytosis exploits receptors highly expressed at the BBB (eg, transferrin receptor). Receptor ligand binding triggers internalization and 
brain delivery. A relatively new mechanism, direct penetration, involves internalization primarily exhibited by CPPs (eg, TAT). Positively charged amino acids (+++) permit 
endocytosis by interacting with the negatively charged endothelial cell membrane (− − −). Once in the brain, multifunctional liposomes can be directed at an appropriate 
target (eg, at Aβ or tau) for AD therapy.
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Liposome delivery for Alzheimer’s disease
Liposome modifications
Liposomes can be functionalized in various ways in order 
to realize their potential as a therapeutic carrier (Figure 2). 
Modification can involve the attachment of molecules to the 
exterior, or the encapsulation of molecules internally, either 
in the aqueous core or lipid bilayers.19 Figure 2 considers 
possible modifications to liposomes that are particularly 
relevant for the treatment of AD.
Stealth liposomes
Simple liposomes are covered by plasma proteins (eg, fibrino-
gen, immunoglobulins, and complement proteins) when 
in circulation, so that a “protein corona” is formed around 
them. This leads to the activation of phagocytic systems and 
removal of these liposomes from the bloodstream.43 In order 
to improve their pharmacokinetic profile and allow longer 
time-periods in circulation, so-called “stealth” liposomes 
were developed, with polyethylene glycol (PEG), or another 
polysaccharide, incorporated into one of the lipid components 
of the liposomal membrane. PEG has high hydration, and 
this increases hydrodynamic volume and allows the forma-
tion of a water cloud around the polymer. Any hydrophilic 
molecule bound covalently to PEG also exhibits these 
properties, providing increased solubility and resistance to 
interaction with plasma proteins. Subsequently, PEGylated 
liposomes in circulation are less prone to formation of a 
protein corona, allowing dramatically improved circulation 
times. However, there is no certainty that these liposomes 
will be transported across the BBB. To provide this, fur-
ther modifications are required, often involving the use of 




The transport of liposomes across the BBB can be facilitated 
by the attachment of appropriate molecules to the lipid 
surface. One of these is GSH, an endogenous tripeptide and 
antioxidant found in almost every cell in the human body. 
Due to its essential protective role in the brain, GSH is trans-
ported actively across the BBB, via a sodium-dependent GSH 
transporter that is highly expressed on the BBB epithelium. 
However, the exact mechanism of action of this transporter 















Figure 2 Promising liposomal modifications for AD therapy.
Notes: These modifications improve their stability and bioavailability, aid BBB transportation, and engage therapeutic targets relevant to treatment of AD. Stability – (a) 
PeGylation. BBB transportation – (b) glutathione, (c) surface antibody, (d) PeG-peptide, (e) PeG-antibody, (f) lactoferrin, (g) glucose, (h) wheat germ agglutinin, (i) PeG-
mApoe, (j) transferrin. Targeting systems for AD – (k) phosphatidic acid, (l) PeG-curcumin, (m) lipophilic peptide, (n) lipophilic drug, (o) hydrophilic peptide, (p) hydrophilic 
drug, (q) nucleic acid.
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PEGylated liposomes with glutathione (GSH-PEG)-mediated 
delivery across the BBB into the brain, and this has shown 
some success in double transgenic APPswe/PS1∆E9 (APP/
PS1) mice,47 but receptor saturation limits this system’s 
effectiveness.48 Additional research is required to enhance 
this strategy further.
Glucose
In a similar way to GSH, there are carrier-mediated transport 
mechanisms in place to facilitate the transport of glucose 
across the BBB, and the incorporation of glucose onto the 
liposome surface can enhance BBB delivery.30 Glucose-
modified PEGylated liposomes prepared with various PEG 
chain lengths have been tested for BBB penetration in mice. 
Results show that liposomes with shorter PEG chain lengths 
have little evidence of brain penetration, because the glu-
cose cannot interact effectively with the BBB surface, and 
therefore cannot utilize the glucose transporter. Longer PEG 
chain lengths are highly flexible and are able to fold back on 
themselves in such a way that the ability to cross the BBB 
is also impaired. Liposomes prepared with medium length 
PEG chains attached to glucose can cross the BBB more 
effectively.49 Thus, liposomal preparations with medium 
length PEGylation are likely to be the most effective method 
for utilizing glucose to enhance BBB transport.
Transferrin (Tf)
Tf is the most commonly targeted receptor (TfR), due to its 
localization on BBB endothelia. This localization is likely to 
be due to Tf’s essential role as an iron-binding blood plasma 
glycoprotein that controls the level of free iron and oxida-
tive stress in the brain, as well as in other tissues.50 Fishman 
et al demonstrated that Tf could cross the BBB via receptor-
mediated endocytosis,51 and more recent studies have shown 
that liposomes modified with Tf can also penetrate the 
BBB in vitro.52,53 However, TfR-mediated endocytosis of 
liposomes is limited due to endogenous Tf competing for 
binding to the TfR.54 This issue can in part be resolved by 
using antibodies that bind with higher affinity than Tf to TfR, 
thus avoiding this competition. Still, Tf is likely to be most 
effective as part of a highly functionalized liposome, where 
multiple modifications allow an additive increase in BBB 
transport; a view supported by recent studies.55,56
Lactoferrin (Lf)
The lactoferrin receptor (LfR), bound by Lf, is also heavily 
overexpressed on the BBB, which has led to the develop-
ment of Lf functionalized liposomes to enhance transport 
into the brain via receptor-mediated endocytosis.57 This 
delivery system has the potential to be particularly efficient, 
as the expression of the LfR on microvessels and neurons is 
increased in AD,58 allowing more effective targeting. Chen 
et al57 investigated the ability of Lf procationic liposomes (Lf-
PCLs) to cross the BBB of rodents, for potential treatment of 
AD. Lf-PCLs become positively charged upon binding to the 
Lf receptor on the BBB epithelium. This allows them to fuse 
more easily with the BBB and overcome disadvantages such 
as non-specific binding and poor stability in circulation.59
mApoe
The ApoE glycoprotein is responsible for the transport and 
delivery of cholesterol and other lipids from the plasma to 
the CNS.60 It contains a peptide binding domain that permits 
BBB transport. A peptide sequence containing this binding 
domain (mApoE) has been used to facilitate BBB transport 
in vitro.61,62 However, the success of this peptide alone to 
facilitate BBB transport is uncertain, as the BBB still limits 
the transport of ApoE, and therefore mApoE, in and out of 
the brain.63 It is likely, therefore, to be used in combination 
with other liposome modifications.
CPPs
In the last 20 years, CPPs have been identified, which are 
able to translocate across biological membranes, including 
the BBB.64 They cross in a non-toxic manner, independent 
of membrane receptors and energy, which could reduce the 
limitations of receptor saturation that have been observed 
with other methods. Most CPPs rely on positively charged 
amino acids interacting with the negatively charged mem-
brane. Arginine and to a lesser extent lysine are particularly 
effective, as they form hydrogen bonds with the negatively 
charged phosphates, which may lead to internalization. 
CPPs with different properties vary in their internalization 
mechanisms (Table 2), but remain similar in their effective 
direct penetration of cell membranes.
Among all CPPs, the HIV-1 tat (TAT) protein has been 
best described and has been used successfully for delivery of 
liposome nanoparticles into the brain.65 TAT triggers steps 
for non-specific endocytotic delivery due to ionic interactions 
between positive charges of the peptide and negative charges 
of the BBB.66 Recent studies have utilized a retro-inverted 
version of TAT, where L-amino acids are replaced with 
D-amino acids, and the sequence is reversed. This reduces 
the potential problems with TAT, such as protease degrada-
tion and poor bioavailability in vivo, but still maintains the 
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Liposome delivery for Alzheimer’s disease
as polyarginines (eg, octa-arginine) and penetratin have also 
shown potential for the delivery of therapeutics directly to 
the brain in SAMP8 mice.68
Multifunctionalized liposomes
Many of the modifications discussed above are likely to 
be more effective as part of a multifunctionalized lipo-
somal system. This will include one or more molecules 
that enhance BBB transport, but most importantly, it will 
allow the incorporation of molecules that permit both BBB 
transport and targeting for AD therapy. The following are 
multifunctionalized liposomal systems that utilize some of 
the modifications discussed above and are in development 
as possible treatments for AD.
Aβ targeting
It is likely that the accumulation and aggregation of Aβ in 
the brain have an important role, directly or indirectly, in the 
induction of synaptic damage and memory deficits in AD.69,70 
The accumulation of Aβ oligomers or fibrils may be caused 
by overproduction, inefficient clearance from the brain, or 
by a combination of both of these. Effective therapeutic 
molecules can have an impact on one of these mechanisms 
to reduce Aβ burden. Many of these molecules on their own 
have low uptake across the BBB, but their incorporation into 
a multifunctionalized liposomal system can help to resolve 
this problem, allowing effective targeting to Aβ.
 mApoe-PA liposomes
Balducci et al71 conducted a key study to look at the ability 
of multifunctional liposomes to target Aβ. These liposomes 
were bi-functionalized with mApoE to enhance crossing 
of the BBB, and with phosphatidic acid (PA), which is a 
high affinity ligand for Aβ.61,71 This bifunctional liposome 
(mApoE-PA-LIP) was able to disaggregate Aβ fibrils in 
vitro, a property that was not exhibited by liposomes mono-
functionalized with either mApoE or PA alone. This syn-
ergistic effect could be due to simultaneous interaction of 
the negatively charged PA phosphate group with positively 
charged amino acid residues on Aβ and of positively charged 
amino acids on mApoE with negatively charged regions of 
Aβ.72 Results from in vivo studies, showing a reduction in 
amyloid plaque load only with mApoE-PA-LIP, are sup-
portive of this idea. However, the uptake of mApoE-PA-LIP 
in the brain was very low, despite the mApoE modification. 
Mancini et al conducted a follow-up investigation on the 
Table 2 Cell-penetrating peptides (CPPs) and their mechanism of internalization
CPP Mechanism Origin References




Pep-1 Pore formation Chimeric 111
Pep-7 Pore formation CHL8 peptide phage clone 112
pveC Transporter mediated Murine endothelial cadherin 113
Transportan endocytosis Galanin-mastoparan 114
Polyarginines Multiple mechanisms Chemically synthesized 108, 115
DPv1047 energy-dependent mechanisms, independent of GAGs  
(charge interactions, HSPH binding)
Chemically synthesized 116
MPG Pore formation HIv glycoprotein 41/Sv40 T  
antigen NLS
117
ARF endocytosis p14 ARF protein 118
p28 Caveolar-mediated/nonclathrin-caveolar-mediated Azurin 119
BPrPr Macropinocytosis (fluid-phase endocytosis) N terminus of unprocessed  
bovine prion protein
120
vT5 Non-specific endocytosis Chemically synthesized 121
Bac 7 Likely non-specific endocytosis Bactenecin family of antimicrobial  
peptides
122
C105Y energy-independent process via caveolin- and clathrin- 
independent lipid rafts
α1-Antitrypsin 123
PFvYLI energy-independent process via caveolin- and clathrin- 
independent lipid rafts
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mechanism behind this therapy, and a strategy known as 
the “sink effect” was proposed, which reduces Aβ burden 
by peripheral administration of a binding agent that draws 
excess Aβ out of the brain (Figure 3).73 The study showed that 
peripheral administration of mApoE-PA-LIP increased the 
level of plasma Aβ without significant amounts of mApoE-
PA-LIP entering the brain. Aβ oligomers were found to be 
transported out of the brain, across the BBB, with mApoE-
PA-LIP acting in the periphery to mediate a fivefold increase 
in this efflux.74
This provides an insight into future therapies that may 
only require sequestration of Aβ in the plasma, without the 
need to cross the BBB. It is evident, however, that this therapy 
might slow down neurodegeneration, but does not eliminate 
the cause of Aβ overproduction. Yet, this bifunctional lipo-
some system provides a valuable insight into future research 
that may effectively prevent amyloid plaque formation.
Curcumin-lipid liposomes
Oxidative damage occurs very early on in course of AD,75,76 
and antioxidants can protect neurons from β-amyloid 
toxicity,77 and so clinical trials involving antioxidants for the 
treatment of AD have been undertaken. So far, these have 
been unsuccessful,78 but the use of curcumin, a turmeric 
derivative, has shown some potential due to its anti-amyloid 
effects.79 This phenolic antioxidant binds to amyloid deposits 
in vitro and in vivo, and it not only disrupts the aggregation 
of the amyloid peptide but also disaggregates pre-formed 
fibrils.80,81 A curcumin analog with a substitution at the C-4 
position has been reported to be more effective in this regard 
than curcumin itself.82
Curcumin has relatively poor bioavailability, hence, lipo-
somal delivery systems for curcumin have been developed 
in an attempt to overcome this.83,84 In the curcumin-lipid 
modified liposome developed by Mourtas et al,84 a PEGylated 
lipid coating provides stealth characteristics and acts as an 
anchor allowing the attachment of anti-transferrin monoclo-
nal antibodies, for mediation of transport across the BBB, in 
addition to a lipid-PEG-curcumin derivative. Results showed 
that this system has high affinity for amyloid plaques and 
reduces amyloid plaque formation in APPswe transgenic 
mice.79 These liposomes may be useful in the future for the 
diagnosis and treatment of AD.
Peptide inhibitor nanoparticles (PINPs)
Austen et al85 showed that a small peptide, named OR2 
(RGKLVFFGR-NH2), inhibits the aggregation of Aβ into 
oligomers and fibrils, and blocks the toxic effects of Aβ 
on cultured cells. However, this peptide is sensitive to 
proteolysis and was not designed to cross the BBB.85 To 
improve its stability, a retro-inverso version (RI-OR2) was 
made,86 and this was enhanced further by the addition of a 
retro-inverted version of TAT to RI-OR2, producing RI-
OR2-TAT (Ac-rGffvlkGrrrrqrrkkrGy-NH2).
67 Following 
its peripheral injection, a fluorescein-labeled version of 
RI-OR2-TAT was found to cross the BBB and bind to the 
amyloid plaques present in the cerebral cortex of APPswe/
PS1∆E9 transgenic mice. Daily intraperitoneal (ip) injection 
Figure 3 The sink effect strategy.
Notes: Aβ assemblies are in equilibrium between the brain and bloodstream, across the BBB endothelium. It is proposed that mApoE-PA modified liposomes sequester 
soluble Aβ (monomers or soluble oligomers) in the peripheral bloodstream, which is then cleared. This creates an imbalance of soluble Aβ. Transport of Aβ from the brain 
to the blood, across the BBB, is then favored, to restore this imbalance. This reduces Aβ burden in the brain and is coined the “sink effect.”
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Liposome delivery for Alzheimer’s disease
of RI-OR2-TAT, for 3 weeks, into these mice resulted in sub-
stantial (25%–45%) reductions in brain Aβ oligomer levels, 
amyloid plaque counts, oxidative damage, and inflammatory 
processes. However, RI-OR2-TAT inhibits Aβ aggregation 
only at relatively high concentrations (ie, at a molar ratio 
of RI-OR2-TAT:Aβ of 1:5 at best) and so its therapeutic 
potential is likely to be limited.67
In order to improve RI-OR2-TAT further, it was 
attached to the surface of stealth liposomes by covalent 
linkage to the PEGylated lipid, via an additional cysteine 
residue on the peptide, to produce PINPs (Figure 4).65 
The presence of the liposome carrier greatly improves the 
potency of RI-OR2-TAT, so that a molar ratio of 1:2,000 of 
liposome-linked inhibitory peptide to Aβ now gives ∼50% 
inhibition of Aβ aggregation. This great increase in potency 
could be due to a multivalent effect. Many copies of the 
RI-OR2-TAT decorate each liposome, which should allow 
the simultaneous interaction of multiple inhibitory peptides 
with any multimeric form of Aβ, thus increasing efficiency 
as an aggregation inhibitor. EM studies have shown that 
PINPs can attach themselves to the free ends of amyloid 
fibrils (Figure 5),87 apparently terminating fibril growth, 
Figure 4 Targeting strategy with PINPs.
Notes: PINPs transport across the BBB by non-specific endocytosis, triggered by positively charged TAT interaction with the negatively charged membrane. RI-OR2-TAT 
inhibitor acts to prevent the aggregation of Aβ into oligomers and fibrils.
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and possibly preventing the formation of Aβ oligomers 
(the free ends of fibrils act as “factories” for generation of 
oligomeric Aβ).88 Studies in transgenic mice have shown 
that peripheral injection of PINPs protects against memory 
loss in TG2576 mice.65 The TAT region of the inhibitory 
peptide facilitates brain penetration, with a brain:blood ratio 
of around 50% being achieved shortly after intravenous 
(iv) injection. However, most of the dose accumulates in 
peripheral tissues, such as lungs, liver, and spleen, most 
likely due to clearance of liposomes via the reticuloen-
dothelial system, and so it is possible that the “sink” effect 
(see above) could explain some of the in vivo properties of 
PINPs. The effectiveness of these PINPS could be improved 
in future by incorporation of alternative or additional brain 
delivery systems.
Neurotransmission targeting
Synaptic loss and degeneration in AD include the loss 
of brain cholinergic neurons, which results in decreased 
acetylcholine (ACh) levels, reduced ACh receptor (AChR) 
density, and an overall decrease in cholinergic neurotrans-
mission. Many limitations and side effects are associated 
with the existing AChEIs that attempt to rebalance cholin-
ergic neurotransmission in AD. They have poor stability in 
circulation, unpredictable uptake and bioavailability, and 
can cause gastrointestinal complications and, occasionally, 
even esophageal tears.89 They also provide only temporarily 
improved cognition. Yet, it may be worthwhile to improve 
these existing therapies, especially since viable alternatives 
have failed to emerge. Subsequently, studies have investi-
gated the potential use of multifunctionalized liposomes, 
incorporating existing drugs, to treat AD.
Rivastigmine-loaded liposomes
Rivastigmine is a reversible, noncompetitive inhibitor of 
brain acetylcholinesterase (AChE).90 As stated previously, 
oral rivastigmine administration has many limitations, such 
as poor stability and low ability to pass through the BBB. 
An alternative intranasal delivery route has shown some 
potential as an alternative for rivastigmine administration.91 
A study from Yang et al92 has considered whether intranasal 
delivery of liposomes loaded with rivastigmine can enhance 
brain delivery and improve therapeutic effect. These lipo-
somes were modified with a PEGylated derivative of a poly-
arginine CPP (DSPE-PEG-CPP) to increase stability and 
enhance BBB delivery, respectively, in an attempt to improve 
the limitations exhibited by the administration of rivastigmine 







Figure 5 Incubation of PINPs with Aβ.
Notes: Figure shows TeM images of negatively stained PINPs. (A) Individual PINPs before incubation with Aβ. (B) Individual PINPs after incubation with Aβ. (C) and (D) 
PINPs after extended incubation with Aβ bound to amyloid fibrils. Scale bars: A and B 150 nm, C and D 100 nm.
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effect of rivastigmine, due to enhanced transcytosis across 
both the BBB and cellular membranes.92
El-Helaly et al94 have reported an alternative modification 
strategy for the intranasal administration of rivastigmine-
loaded liposomes. In order to maintain their stability, a posi-
tively charged inducer called didecyldimethyl ammonium 
bromide was added to these liposomes, leading to electro-
static repulsion and reduced interactions between them. This, 
coupled with the use of a PEGylated lipid, resulted in a highly 
stabile “electrosteric stealth liposome.”93 Results showed a 
fourfold increase in both plasma and brain drug levels, com-
pared to rivastigmine itself. This effect was increased further 
with liposomes bound to Tween 80, a nonionic surfactant 
that has been found to enhance BBB transport.94 Tween 80 
is likely to act as an anchor for apolipoproteins (APO-E and 
APO-B), enhancing BBB transport via receptor-mediated 
endocytosis.95 Further preclinical studies on rivastigmine-
loaded liposomes are required, such as toxicity and dose–
response studies, before they can be considered as suitable 
for therapeutic use.
Liposomes with multiple 
therapeutic targets
Liposomes have great potential for modification, includ-
ing the development of multifunctional liposomes directed 
against more than one therapeutic target. In the case of AD, 
one of the legitimate goals would be to target the formation 
of both Aβ plaques and tau tangles. Theoretically, it is pos-
sible to conceive of a multifunctional liposome that also 
incorporates other therapeutics, such as those directed at the 
ACh system, neuroprotectants, autophagy, anti-inflammatory 
agents, or antioxidants.
wheat germ agglutinin-conjugated 
liposomes
The multifunctional liposomes produced by Kuo et al aim to 
improve the overall neuronal survival in AD by inhibiting the 
phosphorylation of p38 and c-Jun N-terminal kinase (JNK), 
two key members of the mitogen-activated protein kinase 
(MAPK) family, in neurons damaged by the accumulation 


















Figure 6 Cell survival and apoptotic pathway in AD therapy.
Notes: Action of wGA-CRM-CL/LIPs: Curcumin inhibits phosphorylation of JNK and p38, preventing downstream phosphorylation of tau serine 202, leading to prevention 
of apoptotic neurodegeneration. NGF binds TrkA and mediates MAPK phosphorylation cascade and recruitment of CReB, enhancing overall cell survival.
Abbreviations: CL, cardiolipin; CReB, cAMP response element binding protein; CRM, curcumin; JNK, c-Jun N-terminal kinase; LIPs, liposomes; MAPK, mitogen-activated 
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for the understanding of AD progression, since MAPK-
catalyzed phosphorylation events in the brain have a key 
role in the downstream activity of cellular components (eg, 
phosphatases, kinases) that impact on apoptosis and overall 
neuronal survival. It would also provide valuable insight into 
possible future therapies.
The key constituents of this multifunctional liposome 
(coined WGA-CRM-CL/LIP) are curcumin (CRM), nerve 
growth factor (NGF), cardiolipin (CL), and wheat germ 
agglutinin (WGA). In addition to acting as an Aβ aggregation 
inhibitor, curcumin alters the expression of phosphorylated 
p38 (p-p38) and phosphorylated c-Jun N-terminal kinase 
(p-JNK), key players in the apoptotic pathway. NGF pro-
motes the activity of tyrosine kinase receptor type 1 (TrkA), 
which is involved in slowing down neuronal apoptosis. In 
order to enhance the targeting of apoptotic neurons sur-
rounding Aβ, CL was included, as it has a strong affinity 
for Aβ. In this case, both PEGylation and WGA provided 
an additional novel dual functionalization, with the aim of 
improving delivery across the BBB.42
WGA-CRM-CL/LIPs reduced Aβ “plaque” deposition in 
AD model SK-N-MC cells and increased the percentage of 
healthy neurons with cholinergic activity in a Wistar rat AD 
model (established by injection of Aβ into CA1 neurons). 
Additionally, curcumin mediates downstream inhibition of 
tau phosphorylation at serine 202, which is a key site for 
axonogenesis (Figure 6).96 While the therapeutic potential 
of this inhibition is unclear, this is an illustrative method 
of targeting and altering tau phosphorylation, while also 
targeting and reducing Aβ burden. The authors suggest that 
WGA-CRM-CL/LIP should have little effect on a healthy 
brain, since it is not in an inflammatory state and that this 
type of AD therapy would most likely be given to patients 
in the later stages of AD.42
Aβ targeting nanosweepers
Luo et al97 have developed “nanosweepers” (M3) that not 
only capture extracellular Aβ and direct it into cells but also 
upregulate autophagy and digestion of Aβ. The nanosweep-
ers are composed of a cationic chitosan core with PEGylated 
GKLVFF (that can co-assemble with Aβ) and Becln-1 (that 
induces autophagy to degrade Aβ). They work by capturing 
and co-assembling with extracellular Aβ, inhibiting toxic Aβ 
formation, then specifically directing Aβ into cells and acti-
vating autophagy. This strategy has been shown to degrade 
insoluble Aβ from a level of 1,539 down to 914 ng/mg, and 
soluble Aβ from 585 to 190 ng/mg, in APPswe/PS1dE9 
transgenic mice, and also increase neuronal cell viability. 
M3 is a multifunctional peptide-polymer that could provide 
a novel therapeutic approach for the treatment of AD, by 
clearance of Aβ.97 By design, it is not a good aggregation 
inhibitor and could be useful in combination with additional 
therapies.
Future prospects
The majority of studies employing liposomal carrier systems 
to target the CNS are still restricted to early experimental 
work on cell and animal models, or follow on preclinical 
development, with none so far entering human clinical trials. 
Further investment and research is required to develop and 
optimize these carrier systems for AD therapy, since many 
of the studies considered in this article report promising find-
ings, with a drive toward early clinical testing. A reoccurring 
problem is that some of the modifications on their own do not 
allow sufficient penetration through the BBB, or adequate tar-
geting for AD therapy. Since liposomes have great potential 
for heavy functionalization, future steps should incorporate 
several different modifications into the same liposomes that 
can work together in synergy.
Furthermore, current systems in development have tended 
to target only Aβ, due to its fundamental role in AD, yet 
liposomes have the potential to be adapted to incorporate 
a therapeutic cocktail of molecules that aid BBB transport 
and are able to treat multiple areas of AD pathology. Fur-
ther studies could prevent the formation of tau tangles, by 
using an anti-tau antibody, or tau-directed peptides, or small 
molecule inhibitors, in addition to preventing formation 
or dissolution of amyloid plaques, and targeting of phos-
phorylation cascades. A therapeutic system that can target 
Aβ, tau, neuronal survival, and apoptosis, and cholinergic 
neurotransmission, for example, could become the gold 
standard treatment for AD; liposomes are certainly a good 
candidate for the development of such a therapy. CPPs have 
great potential for AD therapy, yet their non-specific uptake 
by peripheral tissue limits their use. TAT peptide, which 
is derived from HIV, is an example of utilizing aspects of 
pathogens for therapeutic purposes. The future of CPPs for 
brain delivery could involve using trans-membrane peptide 
domains derived from trypanosomes,98 or the Zika virus,99 
both of which contain peptides that target enhanced uptake 
into the brain.
Drawbacks and barriers
There remain some issues for liposomes as a drug delivery 
system. There is an increased cost when they are used, but 
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to reach its target with a liposome, but not without, or the 
overall dose may be decreased as a greater proportion of the 
drug reaches its target. They are not suitable for oral delivery 
because they will rupture due to osmotic shock when entering 
the hypotonic environment of the stomach (depending on the 
osmolarity of the internal aqueous filling of the liposome) 
and the lipids will be digested in the small intestine. Once 
in the bloodstream, the majority of liposomes are taken up 
non-specifically by the mononuclear phagocyte system, and 
this includes those with a stealth coating. This reduces the 
number available to be delivered to the brain, although this 
can be overcome by administering a larger dose in a single 
bolus, rather than multiple smaller doses.100 There are two 
main strategies for crossing the BBB (see “BBB transport” 
section) by either targeting a transporter system or by use of 
a CPP. The former approach may lead to saturation of the 
transporter system, whereas this is less of a limiting factor 
in the latter as it is non-specific. Finally, as this is a rela-
tively new technology, there are still some technical issues 
regarding the supply of liposome products to the consumer 
in terms of sterility and product shelf life. Liposomes are 
not suitable for heat sterilization, but bacterial contamina-
tion can be avoided by filtration due to the small size of the 
liposomes.101 In terms of stability, liposomes in suspension 
will eventually start to fuse together, changing the size to the 
point at which they become ineffective as a delivery system. 
To avoid this, the liposomes can be lyophilized or spray dried 
in the presence of trehalose or sucrose and will retain their 
size on rehydration.102,103
Conclusion
Despite these challenges, the use of liposomal carriers is 
proving to be a potentially good strategy for future therapy 
of AD. They have a unique ability for modification to cross 
the BBB, while also showing some evidence of effective-
ness without brain delivery, via the peripheral sink effect. 
Multiple molecules are able to enhance BBB transport, and 
many others allow targeting toward key molecular systems 
involved in AD pathogenesis. It is likely that future develop-
ment will focus mainly on early intervention to slow down the 
progression of this disease, rather than attempting to reverse 
it in more advanced cases. Current study is moving toward 
targeting more than just one aspect of brain pathology, using 
multifunctional liposomes, and this holds great promise for 
the future, but is currently in the very early stages of develop-
ment. Further study and substantial funding will be required 
to achieve success, so that this type of strategy can be driven 
into human clinical trials and beyond.
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